<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d0" for="node" attr.name="label" attr.type="string" />
  <key id="d1" for="node" attr.name="type" attr.type="string" />
  <key id="d2" for="node" attr.name="community" attr.type="string" />
  <key id="d3" for="edge" attr.name="weight" attr.type="double" />
  <key id="d4" for="edge" attr.name="label" attr.type="string" />
  <key id="d5" for="node" attr.name="description" attr.type="string" />
  <key id="d6" for="edge" attr.name="full_description" attr.type="string" />
  <graph id="G" edgedefault="directed">
    <node id="0">
      <data key="d0">CAPRICOR THERAPEUTICS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">Capricor Therapeutics, Inc. is a biopharmaceutical company that is developing a lead cell therapy candidate drug called deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).</data>
    </node>
    <node id="1">
      <data key="d0">LEVI &amp; KORSINSKY</data>
      <data key="d1" />
      <data key="d2">12.0</data>
      <data key="d5" />
    </node>
    <node id="2">
      <data key="d0">U.S. FOOD AND DRUG ADMINISTRATION (FDA)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">The U.S. Food and Drug Administration (FDA) is the regulatory agency responsible for reviewing and approving new drugs and biologics in the United States. The FDA plays a crucial role in ensuring the safety and efficacy of pharmaceutical products before they can be made available to the public.

One of the FDA's key responsibilities is to review Biologics License Applications (BLAs) submitted by pharmaceutical companies seeking approval for their biological products. In the case of Capricor's deramiocel, the FDA denied the company's BLA, citing a lack of substantial evidence of the drug's effectiveness and the need for additional clinical data.

The FDA's decision to deny Capricor's BLA for deramiocel highlights the rigorous standards the agency applies when evaluating new drugs and biologics. The FDA's primary goal is to protect public health by ensuring that only safe and effective products are approved for use. This process can be lengthy and complex, as the FDA must carefully review all available data and evidence to make an informed decision.

Despite the denial of Capricor's BLA, the FDA's role in reviewing and approving new drugs and biologics remains crucial. The agency's oversight helps to ensure that patients have access to safe and effective treatments, while also promoting innovation in the pharmaceutical industry. By maintaining high standards for drug and biologic approval, the FDA plays a vital role in safeguarding the health and well-being of the American public.

In summary, the U.S. Food and Drug Administration is the regulatory agency responsible for reviewing and approving new drugs and biologics in the United States. The FDA's decision to deny Capricor's BLA for deramiocel demonstrates the agency's commitment to ensuring the safety and efficacy of pharmaceutical products, even when it means denying approval for a particular drug or biologic.</data>
    </node>
    <node id="3">
      <data key="d0">DERAMIOCEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">Deramiocel is Capricor Therapeutics' lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cardiomyopathy is a common complication of DMD, a rare and fatal genetic disorder that causes progressive muscle degeneration and weakness.

Deramiocel is a type of cell therapy that uses allogeneic (derived from a different person) cardiosphere-derived cells (CDCs) to target the cardiac complications of DMD. CDCs are a specific type of stem cell that can differentiate into various cardiac cell types, including cardiomyocytes, endothelial cells, and smooth muscle cells. The goal of Deramiocel is to regenerate and repair damaged cardiac tissue in DMD patients, potentially improving heart function and overall quality of life.

Capricor Therapeutics, a clinical-stage biotechnology company, is currently developing Deramiocel as a potential treatment for DMD-associated cardiomyopathy. The company has conducted several clinical trials to evaluate the safety and efficacy of Deramiocel in this patient population. The results of these trials have been promising, suggesting that Deramiocel may have the potential to improve cardiac function and slow the progression of cardiomyopathy in DMD patients.

Overall, Deramiocel represents a novel and innovative approach to addressing the cardiac complications of Duchenne muscular dystrophy, a devastating disease that currently has limited treatment options. As Capricor Therapeutics continues to advance the development of Deramiocel, it holds the promise of providing a much-needed therapeutic option for DMD patients and their families.</data>
    </node>
    <node id="4">
      <data key="d0">DUCHENNE MUSCULAR DYSTROPHY (DMD)</data>
      <data key="d1" />
      <data key="d2">6.0</data>
      <data key="d5" />
    </node>
    <node id="5">
      <data key="d0">LEVI &amp; KORSINSKY, LLP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Levi &amp; Korsinsky, LLP is a law firm that has been actively involved in several legal actions and investigations related to various companies. 

The firm is currently investigating Ultragenyx Pharmaceutical Inc. following the announcement of topline results from its Phase III studies. This investigation is likely related to potential issues or concerns that may have arisen from the company's clinical trial results.

Additionally, Levi &amp; Korsinsky, LLP is representing investors in a class action lawsuit against Altimmune, Inc. This lawsuit suggests that the firm believes there may have been violations of securities laws or other wrongdoings by the company that have adversely affected investors.

The law firm has also filed a class action lawsuit against Vistagen Therapeutics, Inc. on behalf of investors. This indicates that the firm believes there may have been securities fraud or other issues at the company that have impacted shareholders.

Furthermore, Levi &amp; Korsinsky, LLP has commenced an investigation into Alector, Inc. for possible violations of federal securities laws. This investigation suggests that the firm is looking into potential misconduct or irregularities at the company that may have affected investors.

Finally, the law firm has filed a class action lawsuit against Capricor Therapeutics, Inc. on behalf of investors who were allegedly adversely affected by securities fraud. This lawsuit demonstrates the firm's commitment to protecting the rights of investors and holding companies accountable for any fraudulent or unethical practices.

Overall, Levi &amp; Korsinsky, LLP appears to be a law firm that is actively engaged in investigating and pursuing legal action against various companies on behalf of investors. The firm's involvement in these diverse cases suggests that it is dedicated to protecting the interests of shareholders and ensuring that companies adhere to relevant laws and regulations.</data>
    </node>
    <node id="6">
      <data key="d0">JOSEPH E. LEVI</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Joseph E. Levi is an attorney at Levi &amp; Korsinsky, LLP, a law firm that specializes in representing investors and shareholders in various legal matters. Based on the provided descriptions, Mr. Levi is involved in several high-profile cases:

1. Vistagen Therapeutics Shareholders: Mr. Levi is representing shareholders of Vistagen Therapeutics, a biopharmaceutical company, in a legal matter. The nature of the legal matter is not specified, but it is likely related to securities or shareholder rights.

2. Altimmune Lawsuit: Mr. Levi is representing investors in a lawsuit against Altimmune, a clinical-stage biopharmaceutical company. The details of the lawsuit are not provided, but it is likely related to securities or investor protection.

3. Alector, Inc. Investigation: Mr. Levi is investigating a case against Alector, Inc., a biotechnology company. The nature of the investigation is not specified, but it may be related to potential securities violations or other legal issues.

4. Vistagen Therapeutics Class Action Lawsuit: In addition to representing Vistagen Therapeutics shareholders, Mr. Levi is also involved in a class action lawsuit against the company. The specific allegations or claims in this lawsuit are not provided.

5. Capricor Therapeutics Securities Fraud Lawsuit: Mr. Levi is representing investors in a securities fraud lawsuit against Capricor Therapeutics, a clinical-stage biotechnology company. The details of the alleged fraud are not specified.

Despite the multiple cases and legal matters that Mr. Levi is involved in, the descriptions provided do not appear to be contradictory. Rather, they suggest that Mr. Levi is a highly active and experienced attorney who specializes in representing investors and shareholders in the biotechnology and pharmaceutical industries.

In summary, Joseph E. Levi is an attorney at Levi &amp; Korsinsky, LLP who is currently involved in several high-profile legal cases, including representing shareholders and investors in matters related to Vistagen Therapeutics, Altimmune, Alector, Inc., Vistagen Therapeutics (class action), and Capricor Therapeutics. His expertise lies in protecting the rights and interests of investors and shareholders in the biotechnology and pharmaceutical sectors.</data>
    </node>
    <node id="7">
      <data key="d0">ED KORSINSKY</data>
      <data key="d1">PERSON</data>
      <data key="d2">12.0</data>
      <data key="d5">Ed Korsinsky is an attorney at the law firm Levi &amp; Korsinsky, LLP. He has been involved in several high-profile legal cases representing investors and shareholders.

Korsinsky is representing shareholders of Vistagen Therapeutics in a lawsuit. He is also investigating a case against Alector, Inc. and is involved in a class action lawsuit against Vistagen Therapeutics, Inc.

Additionally, Korsinsky is representing investors in the Altimmune lawsuit and the Capricor Therapeutics securities fraud lawsuit. He has extensive experience in handling securities fraud and shareholder rights cases.

Overall, Ed Korsinsky is a seasoned attorney at Levi &amp; Korsinsky who has been actively involved in protecting the rights of investors and shareholders across various industries. His expertise in securities litigation and class action lawsuits has made him a prominent figure in the legal field.</data>
    </node>
    <node id="8">
      <data key="d0">PALISADE-3</data>
      <data key="d1">EVENT</data>
      <data key="d2">23.0</data>
      <data key="d5">The PALISADE-3 was a Phase 3 clinical trial conducted by Vistagen Therapeutics, a biopharmaceutical company, to evaluate its investigational drug fasedienol for the treatment of social anxiety disorder. The clinical trial was a comprehensive study designed to assess the safety and efficacy of fasedienol, a novel drug candidate, in patients with social anxiety disorder.

The PALISADE-3 study was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled a significant number of participants to ensure the robustness of the data. The primary objective of the study was to assess the ability of fasedienol to reduce the symptoms of social anxiety disorder, as measured by established clinical assessment tools.

Fasedienol, the investigational drug being evaluated in the PALISADE-3 trial, is a unique compound that has shown promising results in earlier phases of clinical development. The drug is believed to work by modulating specific neurotransmitter systems in the brain, which are known to play a crucial role in the pathophysiology of social anxiety disorder.

The PALISADE-3 study was an important milestone in the development of fasedienol, as it represented the final stage of clinical testing before the potential submission for regulatory approval. The successful completion of this Phase 3 trial would provide valuable data to support the safety and efficacy of the drug, potentially paving the way for its eventual approval and availability as a new treatment option for individuals suffering from social anxiety disorder.

Vistagen Therapeutics, the sponsor of the PALISADE-3 trial, is a biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. The company's focus on addressing unmet medical needs in the field of mental health and neurological conditions has driven its research and development efforts, including the investigation of fasedienol for the treatment of social anxiety disorder.

In summary, the PALISADE-3 Phase 3 clinical trial was a comprehensive study conducted by Vistagen Therapeutics to evaluate the safety and efficacy of its investigational drug fasedienol for the acute treatment of social anxiety disorder. The successful completion of this trial would represent a significant milestone in the development of a potential new treatment option for individuals struggling with this debilitating condition.</data>
    </node>
    <node id="9">
      <data key="d0">VISTAGEN THERAPEUTICS, INC.</data>
      <data key="d1" />
      <data key="d2">23.0</data>
      <data key="d5" />
    </node>
    <node id="10">
      <data key="d0">MICROSOFT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">Microsoft is a multinational technology company that develops and sells a wide range of software, hardware, and services. The company is best known for its Windows operating system, Office productivity suite, and Azure cloud computing platform.

Founded in 1975 by Bill Gates and Paul Allen, Microsoft has grown to become one of the largest and most influential technology companies in the world. The company's mission is to empower every person and organization on the planet to achieve more.

Microsoft's product portfolio includes a diverse range of offerings, from desktop and mobile operating systems to productivity tools, enterprise software, and cloud-based services. The Windows operating system is the most widely used desktop OS in the world, powering millions of personal computers and devices. The Office suite, including applications like Word, Excel, and PowerPoint, is a staple in both personal and professional settings.

In recent years, Microsoft has made significant investments in cloud computing, with its Azure platform emerging as a major competitor to Amazon Web Services and Google Cloud. Azure provides a comprehensive suite of cloud-based services, including infrastructure-as-a-service (IaaS), platform-as-a-service (PaaS), and software-as-a-service (SaaS) offerings, catering to the needs of businesses of all sizes.

Beyond its core software and cloud offerings, Microsoft also develops and sells a range of hardware products, including the Surface line of tablets and laptops, the Xbox gaming console, and various peripherals such as mice and keyboards.

The company's commitment to innovation and technological advancement has been a driving force behind its success. Microsoft has consistently invested in research and development, enabling it to stay at the forefront of emerging technologies and trends, such as artificial intelligence, mixed reality, and the Internet of Things.

Despite its dominant position in the technology industry, Microsoft has faced its fair share of challenges and controversies over the years, including antitrust investigations, privacy concerns, and the need to adapt to rapidly changing market conditions. However, the company has demonstrated its resilience and ability to evolve, continuously reinventing itself to meet the needs of its customers and stay competitive in an ever-changing landscape.

Overall, Microsoft's comprehensive product portfolio, innovative spirit, and global reach make it a formidable player in the technology industry, with a significant impact on both the personal and professional lives of people around the world.</data>
    </node>
    <node id="11">
      <data key="d0">UNIVERSITY OF FLORIDA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">The University of Florida is a public research university located in Gainesville, Florida. It is one of the largest and most prestigious universities in the United States, known for its strong academic programs, diverse student body, and successful athletic teams.

However, the University of Florida has recently faced legal challenges related to the operation of its official website. According to reports, the university's website was found to have improper tracking mechanisms, leading to a class action lawsuit filed by the law firm Levi &amp; Korsinsky.

The lawsuit alleges that the University of Florida's website violated the Video Privacy Protection Act (VPPA), a federal law that restricts the disclosure of personal information related to a person's video viewing habits. The lawsuit claims that the university's website was collecting and sharing user data, including information about the videos and content that users were accessing, without their knowledge or consent.

The class action lawsuit seeks to hold the University of Florida accountable for these alleged violations and to provide compensation to the affected individuals. The university has not yet issued a formal response to the lawsuit, but it is likely that they will work to address the concerns raised and ensure that their website is in compliance with all relevant laws and regulations.

Despite this legal issue, the University of Florida remains a highly respected institution of higher education. It is known for its strong programs in fields such as engineering, medicine, business, and the sciences, and it attracts students from all over the world. The university also has a vibrant campus life, with a wide range of student organizations, cultural events, and recreational activities.

Overall, the University of Florida is a complex and multifaceted institution that has faced some challenges related to its online presence, but it continues to be a leading center of learning and research in the United States.</data>
    </node>
    <node id="12">
      <data key="d0">UNIVERSITY OF TEXAS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">The University of Texas is one of the college athletic programs whose official website was targeted by Levi &amp; Korsinsky in a class action lawsuit for alleged violations of the Video Privacy Protection Act (VPPA)</data>
    </node>
    <node id="13">
      <data key="d0">UNIVERSITY OF NEBRASKA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">The University of Nebraska is one of the college athletic programs whose official website was targeted by Levi &amp; Korsinsky in a class action lawsuit for alleged violations of the Video Privacy Protection Act (VPPA)</data>
    </node>
    <node id="14">
      <data key="d0">UNIVERSITY OF SOUTHERN CALIFORNIA (USC)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">The University of Southern California (USC) is a prominent higher education institution that has recently faced legal challenges related to its website operations. According to the information provided, USC's college athletic program was targeted in a class action lawsuit filed by Levi &amp; Korsinsky, a law firm.

The lawsuit alleges that USC's official website violated the Video Privacy Protection Act (VPPA) and improperly utilized Google's Programmable Search Engine. The VPPA is a federal law that restricts the disclosure of individuals' video rental or purchase records without their consent.

The class action lawsuit claims that USC's website engaged in improper tracking practices, leading to the alleged violations of the VPPA. This suggests that the university's website may have collected or shared users' personal information or viewing habits without their knowledge or consent.

The lawsuit against USC is part of a broader trend of legal actions targeting universities and other organizations for their online data collection and usage practices. As more individuals become aware of privacy concerns in the digital age, there is an increased focus on ensuring that websites and online services adhere to relevant laws and regulations.

It is important to note that the allegations made in the lawsuit have not been proven in court, and USC has not yet had the opportunity to respond to the claims. The university may have valid explanations or defenses for the alleged actions, and the final outcome of the case remains to be determined.

In summary, the University of Southern California (USC) has been named in a class action lawsuit alleging violations of the Video Privacy Protection Act and improper use of Google's Programmable Search Engine on its official website. The lawsuit claims that USC's website engaged in unauthorized tracking and data collection practices, though the university has not yet had the chance to address these allegations. This case highlights the growing concerns around online privacy and the need for organizations to carefully manage their digital practices to ensure compliance with relevant laws and regulations.</data>
    </node>
    <node id="15">
      <data key="d0">LEARFIELD</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Learfield is a company that manages the official websites of college athletic programs. The company has been the subject of class action lawsuits filed by the law firm Levi &amp; Korsinsky.

According to the descriptions provided, Learfield operates websites on behalf of college athletic programs. These websites have been found to engage in improper tracking practices, leading to the class action lawsuits brought by Levi &amp; Korsinsky.

The lawsuits allege that Learfield's websites have been using tracking technologies in a way that violates the privacy and consent of users. This could include the use of cookies, web beacons, or other methods to collect and share user data without proper disclosure or authorization.

While the specific details of the lawsuits are not provided, it seems that Learfield's management of the college athletic program websites has led to concerns about the handling of user information and potential violations of privacy laws or regulations.

Learfield is a company that provides a range of services to college athletic programs, including managing their official websites and digital platforms. The company's role in operating these websites has now come under scrutiny due to the class action lawsuits filed by Levi &amp; Korsinsky.

Overall, the summary indicates that Learfield is facing legal challenges related to the tracking and data collection practices on the college athletic program websites it manages. The company will likely need to address these concerns and ensure that its digital platforms are operating in compliance with relevant privacy laws and regulations.</data>
    </node>
    <node id="16">
      <data key="d0">SIDEARM SPORTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Sidearm Sports is a company that operates and manages the official websites of various college athletic programs. The company has been the subject of several privacy-related lawsuits brought by the law firm Levi &amp; Korsinsky.

According to the information provided, Sidearm Sports is a subsidiary of the larger media and technology company Learfield. The company's primary business is to manage and operate the official websites of college athletic departments. These websites are used by the colleges to provide information, news, and other content related to their sports teams and programs.

The key issue that has led to the lawsuits against Sidearm Sports is the alleged improper tracking and data collection practices on these college athletic websites. The lawsuits, which have been filed as class actions, claim that Sidearm Sports has implemented tracking technologies and data collection methods on the websites it manages without proper disclosure or consent from website visitors.

The lawsuits allege that Sidearm Sports has been collecting and sharing personal information and browsing data of website users, including students, alumni, and fans of the colleges, without their knowledge or permission. This has been seen as a violation of privacy rights and has led to the class action lawsuits filed by Levi &amp; Korsinsky on behalf of affected individuals.

While the specific details and outcomes of the lawsuits are still unfolding, the core issue appears to be Sidearm Sports' data collection and privacy practices on the college athletic websites it manages. The company's role as a subsidiary of Learfield and its position as a provider of website management services to colleges have made it a target for these privacy-related legal actions.

It is important to note that the information provided does not indicate any final rulings or conclusions regarding the lawsuits. The situation is still ongoing, and the ultimate resolution of the legal disputes remains to be seen. Sidearm Sports may have the opportunity to address the concerns raised and potentially find a resolution with the plaintiffs.

In summary, Sidearm Sports is a company that manages the official websites of various college athletic programs, and it has been the subject of class action lawsuits alleging improper data collection and privacy violations on these websites. The company's role as a subsidiary of Learfield and its position as a provider of website management services have made it a target for these legal actions.</data>
    </node>
    <node id="17">
      <data key="d0">META</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Meta (formerly Facebook) is a social media and technology company that operates platforms such as Facebook, Instagram, and WhatsApp. The company has been the subject of class action lawsuits led by Levi &amp; Korsinsky, related to the use of its Facebook Pixel tracking technology.

The Facebook Pixel is a tool provided by Meta that allows website owners to track user behavior and interactions on their sites. However, the use of this technology has been the subject of controversy, with allegations that it was used on college athletic program websites without proper user consent.

According to the class action lawsuits, the Facebook Pixel was allegedly used to collect and track user data from these college athletic program websites, without the knowledge or consent of the users. This has led to claims that Meta's practices have violated user privacy and data protection laws.

Despite these legal challenges, Meta continues to be a dominant player in the social media and technology industry. The company operates a range of platforms, including the flagship Facebook social network, as well as Instagram and WhatsApp, which are widely used for communication, sharing content, and engaging with others online.

While the legal issues surrounding the use of the Facebook Pixel are still ongoing, Meta remains a significant force in the technology sector, with a vast user base and a range of products and services that have become integral to the digital lives of millions of people around the world.</data>
    </node>
    <node id="18">
      <data key="d0">GOOGLE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">13.0</data>
      <data key="d5">Google is a technology company that has faced legal challenges related to its Programmable Search Engine technology. According to the provided descriptions, Google's Programmable Search Engine has been implicated in class action lawsuits led by the law firm Levi &amp; Korsinsky.

Specifically, the descriptions indicate that Google's Programmable Search Engine technology was allegedly used on the University of Southern California (USC) website without proper user consent, leading to a class action lawsuit filed by Levi &amp; Korsinsky. The lawsuit claims that Google's technology was used in a way that violated user privacy and consent.

While the descriptions do not provide detailed information about the specific allegations or the outcomes of the lawsuits, they suggest that Google's Programmable Search Engine technology has been the subject of legal scrutiny and potential misuse. The company's role as a technology provider and the alleged use of its tools without proper user consent have led to these legal challenges.

It is important to note that the descriptions provided do not contain any contradictory information, and the summary presented here is a coherent and comprehensive representation of the data given. However, it is possible that additional information or context may be required to fully understand the nature and status of the legal issues surrounding Google's Programmable Search Engine technology.</data>
    </node>
    <node id="19">
      <data key="d0">GENERAL CONSUMER PROTECTION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Levi &amp; Korsinsky's consumer protection team targets companies for product defects, overcharging, deceptive marketing, and data breaches</data>
    </node>
    <node id="20">
      <data key="d0">XEROX HOLDINGS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Xerox Holdings is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2025</data>
    </node>
    <node id="21">
      <data key="d0">DZS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">DZS Inc. was the subject of consolidated securities fraud actions led by Levi &amp; Korsinsky in 2024</data>
    </node>
    <node id="22">
      <data key="d0">LILIUM N.V.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Lilium N.V. is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2024, alleging overstated fundraising progress and failure to disclose insolvency risks</data>
    </node>
    <node id="23">
      <data key="d0">ILEARNINGENGINES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">iLearningEngines, Inc. is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2024, alleging the company overstated revenue using a related party to report "largely fake" financials</data>
    </node>
    <node id="24">
      <data key="d0">IRIS ENERGY LIMITED</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Iris Energy Limited is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2024, alleging the company overstated its data center and high-performance computing prospects due to deficiencies at its Childress County, Texas site</data>
    </node>
    <node id="25">
      <data key="d0">CEREVEL THERAPEUTICS HOLDINGS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Cerevel Therapeutics Holdings, Inc. is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2025, alleging misleading statements related to a merger with AbbVie Inc.</data>
    </node>
    <node id="26">
      <data key="d0">VIATRIS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Viatris Inc. is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2025, alleging the company downplayed the impact of a warning letter and import alert affecting its Indore facility</data>
    </node>
    <node id="27">
      <data key="d0">THE SOUTHERN COMPANY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">The Southern Company is a company that was the subject of a class action lawsuit led by Levi &amp; Korsinsky in 2022, alleging misleading statements in audits of the company's financials, particularly regarding its Kemper, Mississippi "clean coal" plant</data>
    </node>
    <node id="28">
      <data key="d0">DELOITTE &amp; TOUCHE, LLP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Deloitte &amp; Touche, LLP is an auditing firm that was a defendant in the class action lawsuit against The Southern Company</data>
    </node>
    <node id="29">
      <data key="d0">PURECYCLE TECHNOLOGIES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">PureCycle Technologies, Inc. is a company that was the subject of a stockholder derivative suit settlement led by Levi &amp; Korsinsky in 2023, related to the company's polypropylene recycling processes</data>
    </node>
    <node id="30">
      <data key="d0">ALIGN TECHNOLOGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Align Technology is a company whose executives were named as defendants in a class action lawsuit led by Levi &amp; Korsinsky in 2018</data>
    </node>
    <node id="31">
      <data key="d0">TRANSOCEAN LTD.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Transocean Ltd. is a company whose executives were named as defendants in a class action lawsuit led by Levi &amp; Korsinsky in 2023</data>
    </node>
    <node id="32">
      <data key="d0">LILIUM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Lilium is an emerging company that has been a defendant in securities cases brought by Levi &amp; Korsinsky</data>
    </node>
    <node id="33">
      <data key="d0">ILEARNINGENGINES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">iLearningEngines is an emerging company that has been a defendant in securities cases brought by Levi &amp; Korsinsky</data>
    </node>
    <node id="34">
      <data key="d0">XEROX</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Xerox is an established firm that has been a defendant in securities cases brought by Levi &amp; Korsinsky</data>
    </node>
    <node id="35">
      <data key="d0">VIATRIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Viatris is an established firm that has been a defendant in securities cases brought by Levi &amp; Korsinsky</data>
    </node>
    <node id="36">
      <data key="d0">IRIS ENERGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Iris Energy is a company that has been the target of a recent securities class action filing by Levi &amp; Korsinsky</data>
    </node>
    <node id="37">
      <data key="d0">DZS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">DZS is a company where Levi &amp; Korsinsky has been appointed as lead counsel in a securities case</data>
    </node>
    <node id="38">
      <data key="d0">HOPE-2 TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">6.0</data>
      <data key="d5">The HOPE-2 TRIAL was a Phase 2 clinical trial conducted by Capricor to evaluate the safety and efficacy of deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

The HOPE-2 trial was a Phase 2 clinical study that aimed to assess the safety and effectiveness of deramiocel, a cell therapy product developed by Capricor, in treating the cardiomyopathy (heart muscle disease) that often accompanies DMD. DMD is a rare and severe genetic disorder that primarily affects boys, causing progressive muscle weakness and degeneration.

The trial enrolled participants with DMD and cardiomyopathy to receive either deramiocel or a placebo (a non-active treatment) through intravenous infusion. The primary outcome measures of the study were to evaluate the safety and tolerability of deramiocel, as well as its potential to improve cardiac function and exercise capacity in the participants.

Deramiocel is a type of cell therapy that utilizes cardiosphere-derived cells (CDCs), which are extracted from a patient's own heart tissue and then expanded in the laboratory. The goal of this approach is to harness the regenerative and reparative properties of these cells to potentially improve cardiac function and mitigate the progression of cardiomyopathy in individuals with DMD.

The HOPE-2 trial was designed to build upon the promising results observed in the earlier HOPE-Duchenne trial, which had demonstrated the safety and potential efficacy of deramiocel in a smaller cohort of DMD patients with cardiomyopathy.

By conducting the larger-scale HOPE-2 trial, Capricor aimed to further investigate the therapeutic potential of deramiocel and its ability to address the significant unmet medical need in the management of DMD-associated cardiomyopathy. The comprehensive data collected from this trial will help inform the future development and potential regulatory approval of deramiocel as a novel treatment option for this debilitating condition.

The HOPE-2 trial represents an important step forward in the ongoing efforts to improve the quality of life and clinical outcomes for individuals living with Duchenne muscular dystrophy and the associated cardiac complications.</data>
    </node>
    <node id="39">
      <data key="d0">FDA</data>
      <data key="d1" />
      <data key="d2">6.0</data>
      <data key="d5" />
    </node>
    <node id="40">
      <data key="d0">BIOLOGICS LICENSE APPLICATION (BLA)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">A Biologics License Application (BLA) is a regulatory submission to the U.S. Food and Drug Administration (FDA) for the approval of a biological product, such as a cell therapy. It is a request for permission to introduce or deliver a biologic product into interstate commerce.

The BLA process is a comprehensive regulatory pathway that requires the applicant to provide extensive data and information to demonstrate the safety, purity, and potency of the biological product. This includes details on the product's manufacturing process, quality control measures, and preclinical and clinical trial results.

The BLA submission must include a detailed description of the product, including its composition, mechanism of action, and intended use. The applicant must also provide information on the facilities and equipment used in the manufacturing process, as well as the qualifications of the personnel involved.

The FDA's review of a BLA involves a thorough evaluation of the submitted data to ensure that the product meets the necessary standards for safety, efficacy, and quality. This process can be lengthy and complex, often taking several months to a year or more for the FDA to reach a decision.

Once a BLA is approved, the biological product can be marketed and distributed in the United States. The approval is specific to the product, the manufacturing process, and the facilities used to produce it. Any changes to these elements may require the submission of a new BLA or a supplement to the existing one.

In summary, the Biologics License Application (BLA) is a critical regulatory process that allows for the introduction of biological products, such as cell therapies, into the U.S. market. It ensures that these products meet the necessary standards for safety, efficacy, and quality, as determined by the FDA's comprehensive review and approval.</data>
    </node>
    <node id="41">
      <data key="d0">COMPLETE RESPONSE LETTER (CRL)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">6.0</data>
      <data key="d5">The Complete Response Letter (CRL) is a communication from the U.S. Food and Drug Administration (FDA) to an applicant regarding a Biologics License Application (BLA). The CRL indicates that the application is not ready for approval in its present form, and the review cycle for the application is complete.

The CRL is a formal notification from the FDA to the applicant, informing them that the BLA cannot be approved in its current state. This letter outlines the specific deficiencies or issues that the FDA has identified during the review process, which need to be addressed by the applicant before the application can be reconsidered for approval.

The CRL serves as a critical step in the regulatory approval process for biological products, such as vaccines, therapeutic proteins, and other complex biological entities. It provides the applicant with a clear understanding of the outstanding concerns or requirements that must be met before the FDA can grant approval for the product.

Upon receiving a CRL, the applicant is expected to address the identified issues and resubmit the application for further review. This may involve conducting additional studies, providing more data, or making necessary changes to the product or its manufacturing process. The applicant must then respond to the CRL within a specified timeframe, typically within a few months, in order to continue the review process.

The CRL is an important communication that helps to ensure the safety, efficacy, and quality of biological products before they are approved for commercial use. By providing detailed feedback and guidance, the FDA aims to work collaboratively with applicants to address any concerns and ultimately bring safe and effective biological products to the market.</data>
    </node>
    <node id="42">
      <data key="d0">NVIDIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">NVIDIA is a technology company that designs and manufactures graphics processing units (GPUs) and related hardware for the gaming, professional, and data center markets.</data>
    </node>
    <node id="43">
      <data key="d0">ORACLE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">Oracle is a multinational computer technology corporation that specializes in developing and marketing database software and technology, cloud engineered systems, and enterprise software products.</data>
    </node>
    <node id="44">
      <data key="d0">TESLA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">Tesla is an American electric vehicle and clean energy company that designs and manufactures electric cars, energy storage products, and related products.</data>
    </node>
    <node id="45">
      <data key="d0">CLOUDQUOTE.IO</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">CloudQuote.io is a provider of stock quote and news APIs.</data>
    </node>
    <node id="46">
      <data key="d0">GOOG</data>
      <data key="d1" />
      <data key="d2">13.0</data>
      <data key="d5" />
    </node>
    <node id="47">
      <data key="d0">FINANCIAL CONTENT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">FinancialContent is the company that provides the stock quote and news APIs used in the text.</data>
    </node>
    <node id="48">
      <data key="d0">FASEDIENOL</data>
      <data key="d1" />
      <data key="d2">23.0</data>
      <data key="d5" />
    </node>
    <node id="49">
      <data key="d0">QUANTUMSCAPE CORPORATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">QuantumScape Corporation is a company that was involved in a $47.5 million settlement</data>
    </node>
    <node id="50">
      <data key="d0">LOMA NEGRA INDUSTRIAL ARGENTINA SOCIEDAD ARGENTINA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Loma Negra Industrial Argentina Sociedad Argentina was involved in a $24.6 million settlement</data>
    </node>
    <node id="51">
      <data key="d0">CORCEPT THERAPEUTICS INCORPORATED</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Corcept Therapeutics Incorporated was involved in a $14 million settlement</data>
    </node>
    <node id="52">
      <data key="d0">BABCOCK &amp; WILCOX ENTERPRISES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Babcock &amp; Wilcox Enterprises, Inc. was involved in a $9.5 million settlement</data>
    </node>
    <node id="53">
      <data key="d0">U.S. STEEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">U.S. Steel was involved in a $40 million settlement</data>
    </node>
    <node id="54">
      <data key="d0">AQUA METALS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Aqua Metals, Inc. was involved in a $7 million settlement</data>
    </node>
    <node id="55">
      <data key="d0">WIDEOPENWEST, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">WideOpenWest, Inc. was involved in a $7.025 million settlement</data>
    </node>
    <node id="56">
      <data key="d0">HELIOS AND MATHESON ANALYTICS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Helios and Matheson Analytics Inc. was involved in an $8.25 million settlement</data>
    </node>
    <node id="57">
      <data key="d0">ILLUMINA, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Illumina, Inc. was involved in a $13.85 million settlement</data>
    </node>
    <node id="58">
      <data key="d0">AVON PRODUCTS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Avon Products Inc. was involved in a $14.5 million settlement</data>
    </node>
    <node id="59">
      <data key="d0">RONALD B. RUBIN</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Ronald B. Rubin is a judge who praised the handling of a case</data>
    </node>
    <node id="60">
      <data key="d0">TIMOTHY S. DRISCOLL</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Timothy S. Driscoll is a judge who praised the conduct of the legal profession in a case</data>
    </node>
    <node id="61">
      <data key="d0">ANDREW L. CARTER, JR.</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Andrew L. Carter, Jr. is a judge who found the firm to be well-qualified to serve as Lead Counsel</data>
    </node>
    <node id="62">
      <data key="d0">ANALISA TORRES</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Analisa Torres is a judge who noted the firm's "extensive experience" in securities litigation</data>
    </node>
    <node id="63">
      <data key="d0">BARRY TED MOSKOWITZ</data>
      <data key="d1">PERSON</data>
      <data key="d2">16.0</data>
      <data key="d5">Barry Ted Moskowitz is a judge who found the class counsel to be skilled and adequate to represent the settlement class</data>
    </node>
    <node id="64">
      <data key="d0">DRUG TRIAL</data>
      <data key="d1" />
      <data key="d2">23.0</data>
      <data key="d5" />
    </node>
    <node id="65">
      <data key="d0">MARCH 16 2026</data>
      <data key="d1">EVENT</data>
      <data key="d2">23.0</data>
      <data key="d5">Deadline for filing class action lawsuit against Vistagen Therapeutics, Inc. and Smart Digital Group Limited</data>
    </node>
    <node id="66">
      <data key="d0">TRONOX HOLDINGS PLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">18.0</data>
      <data key="d5">Tronox Holdings PLC is a company that has been the subject of a securities class action lawsuit. According to the provided descriptions, investors have filed a federal securities class action lawsuit against Tronox Holdings PLC. The law firm Levi &amp; Korsinsky served as lead counsel in this securities class action lawsuit against the company.

The details of the lawsuit are not explicitly stated in the given information, but the descriptions indicate that Tronox Holdings PLC is facing legal action from its investors related to securities or financial matters. Securities class action lawsuits are typically filed when a company is alleged to have made false or misleading statements, or engaged in other misconduct, that resulted in financial losses for investors.

While the specific allegations or claims made in the lawsuit are not provided, the fact that multiple descriptions reference a securities class action lawsuit against Tronox Holdings PLC suggests that the company has been accused of some form of wrongdoing or misrepresentation that has negatively impacted its investors.

In summary, Tronox Holdings PLC is a company that has been the subject of a securities class action lawsuit, with investors filing a federal lawsuit against the company. The law firm Levi &amp; Korsinsky served as lead counsel in this legal action. The details of the lawsuit and the specific allegations against Tronox Holdings PLC are not explicitly stated in the provided information, but the descriptions indicate that the company is facing legal challenges related to its securities or financial matters.</data>
    </node>
    <node id="67">
      <data key="d0">KELLER V. TRONOX HOLDINGS PLC</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">Keller v. Tronox Holdings PLC is a putative federal securities class action lawsuit</data>
    </node>
    <node id="68">
      <data key="d0">SOCIAL ANXIETY DISORDER</data>
      <data key="d1">EVENT</data>
      <data key="d2">23.0</data>
      <data key="d5">Social anxiety disorder is the condition that Vistagen's drug fasedienol was being developed to treat</data>
    </node>
    <node id="69">
      <data key="d0">ALECTOR, INC.</data>
      <data key="d1" />
      <data key="d2">17.0</data>
      <data key="d5" />
    </node>
    <node id="70">
      <data key="d0">LATOZINEMAB (AL001)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">17.0</data>
      <data key="d5">Latozinemab (AL001) is a drug developed by Alector, Inc. to treat frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </node>
    <node id="71">
      <data key="d0">FRONTOTEMPORAL DEMENTIA DUE TO A PROGRANULIN GENE MUTATION (FTD-GRN)</data>
      <data key="d1">EVENT</data>
      <data key="d2">17.0</data>
      <data key="d5">The clinical trial for latozinemab (AL001) was evaluating its efficacy in treating frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </node>
    <node id="72">
      <data key="d0">WALLACE CALVIN ABBOTT</data>
      <data key="d1">PERSON</data>
      <data key="d2">0.0</data>
      <data key="d5">Wallace Calvin Abbott founded Abbott Laboratories in 1888.</data>
    </node>
    <node id="73">
      <data key="d0">ABBOTT PARK</data>
      <data key="d1">GEO</data>
      <data key="d2">0.0</data>
      <data key="d5">Abbott Laboratories is headquartered in Abbott Park, Illinois.</data>
    </node>
    <node id="74">
      <data key="d0">ABBOTT LABORATORIES</data>
      <data key="d1" />
      <data key="d2">0.0</data>
      <data key="d5" />
    </node>
    <node id="75">
      <data key="d0">ESTABLISHED PHARMACEUTICAL PRODUCTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets.</data>
    </node>
    <node id="76">
      <data key="d0">DIAGNOSTIC PRODUCTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites.</data>
    </node>
    <node id="77">
      <data key="d0">NUTRITIONAL PRODUCTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products.</data>
    </node>
    <node id="78">
      <data key="d0">MEDICAL DEVICES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders.</data>
    </node>
    <node id="79">
      <data key="d0">JANUX THERAPEUTICS INC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Janux Therapeutics Inc is a healthcare company</data>
    </node>
    <node id="80">
      <data key="d0">BICRYST</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">BioCryst is a healthcare company</data>
    </node>
    <node id="81">
      <data key="d0">EXACT SCIENCES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Exact Sciences is a healthcare company</data>
    </node>
    <node id="82">
      <data key="d0">TELIX PHARMACEUTICALS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Telix Pharmaceuticals is a healthcare company</data>
    </node>
    <node id="83">
      <data key="d0">DEXCOM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">DexCom is a healthcare company</data>
    </node>
    <node id="84">
      <data key="d0">AMGEN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Amgen is a healthcare company</data>
    </node>
    <node id="85">
      <data key="d0">ANNEXON BIOSCIENCES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Annexon Biosciences is a healthcare company</data>
    </node>
    <node id="86">
      <data key="d0">BERNSTEIN LIEBHARD LLP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Bernstein Liebhard LLP is a law firm that specializes in representing investors in class action lawsuits. The firm has filed a securities class action lawsuit against Abbott Laboratories, a major pharmaceutical company.

According to the provided descriptions, Bernstein Liebhard LLP is a law firm that is currently involved in a class action lawsuit against Abbott Laboratories. The firm is representing investors in this lawsuit, which appears to be a securities class action lawsuit. The firm has filed the lawsuit and is also reminding investors of the deadline to file a lead plaintiff motion in the case.

The descriptions indicate that Bernstein Liebhard LLP is taking legal action against Abbott Laboratories on behalf of investors. The firm is likely alleging that Abbott Laboratories has engaged in some form of securities fraud or other misconduct that has harmed investors. By filing a class action lawsuit, Bernstein Liebhard LLP is seeking to represent a group of investors who have been affected by Abbott Laboratories' actions and to recover damages on their behalf.

Overall, Bernstein Liebhard LLP is a law firm that is actively involved in a securities class action lawsuit against Abbott Laboratories, with the goal of protecting the interests of investors who have been harmed by the company's alleged misconduct.</data>
    </node>
    <node id="87">
      <data key="d0">SHAREHOLDERS FOUNDATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Shareholders Foundation is an organization that represents shareholders</data>
    </node>
    <node id="88">
      <data key="d0">BANK OF AMERICA SECURITIES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Bank of America Securities is a financial services company</data>
    </node>
    <node id="89">
      <data key="d0">BTIG</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">BTIG is a financial services company</data>
    </node>
    <node id="90">
      <data key="d0">MIZUHO</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">10.0</data>
      <data key="d5">Mizuho is a prominent financial services company based in Japan. The entity descriptions provided indicate that Mizuho is engaged in various financial activities, including highlighting advancements in quantum computing technology.

Mizuho is a diversified financial institution that offers a wide range of services to its clients. As a financial services company, Mizuho is involved in traditional banking, investment, and asset management activities. The company's operations span across various sectors, including corporate banking, retail banking, and capital markets.

In addition to its core financial services, Mizuho has also been at the forefront of technological advancements in the industry. The entity descriptions suggest that Mizuho has highlighted progress in the field of quantum computing, which has the potential to revolutionize various aspects of the financial sector, such as risk management, portfolio optimization, and financial modeling.

Quantum computing is an emerging technology that leverages the principles of quantum mechanics to perform computations more efficiently than classical computers. This technology has the ability to solve complex problems that are intractable for traditional computers, making it particularly valuable in the financial industry, where the ability to process large amounts of data and make rapid decisions is crucial.

By highlighting its advancements in quantum computing, Mizuho demonstrates its commitment to staying at the forefront of technological innovation and its willingness to explore new avenues to enhance its service offerings and competitive edge in the financial market.

Overall, Mizuho is a comprehensive financial services company that operates across a diverse range of business lines, while also actively engaging in the development and application of cutting-edge technologies, such as quantum computing, to better serve its clients and stay ahead of the curve in the rapidly evolving financial landscape.</data>
    </node>
    <node id="91">
      <data key="d0">PIPER SANDLER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Piper Sandler is a financial services company</data>
    </node>
    <node id="92">
      <data key="d0">BERNSTEIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Bernstein is a financial services company</data>
    </node>
    <node id="93">
      <data key="d0">CITI</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Citi is a financial services company</data>
    </node>
    <node id="94">
      <data key="d0">WELLS FARGO</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Wells Fargo is a financial services company</data>
    </node>
    <node id="95">
      <data key="d0">POMERANTZ LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Pomerantz Law Firm is a legal practice that has been involved in several high-profile cases on behalf of investors. According to the provided information, the firm has been investigating claims related to two different entities: Abbott Laboratories and IonQ, Inc.

Regarding Abbott Laboratories, the Pomerantz Law Firm is investigating potential claims on behalf of investors. The nature and details of these claims are not specified in the given information.

With respect to IonQ, Inc., the Pomerantz Law Firm appears to be more actively involved. The firm is representing IonQ investors in a class action lawsuit and has been reminding shareholders of the ongoing legal proceedings and upcoming deadlines. The firm is representing IonQ shareholders who have experienced losses on their investments in the company.

It is important to note that the provided descriptions do not contain any contradictory information. The Pomerantz Law Firm's involvement with IonQ is consistently described across the different statements, indicating that the firm is actively representing IonQ shareholders in a class action lawsuit.

In summary, the Pomerantz Law Firm is a legal practice that has been involved in investigating claims on behalf of investors of Abbott Laboratories, as well as representing IonQ shareholders in a class action lawsuit related to losses on their investments in the company. The firm is actively engaged in the IonQ case, reminding shareholders of the ongoing legal proceedings and upcoming deadlines.</data>
    </node>
    <node id="96">
      <data key="d0">ROSEN, GLOBAL INVESTOR COUNSEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Rosen, Global Investor Counsel is encouraging Abbott Laboratories investors to secure counsel before the October 31 deadline in the securities class action</data>
    </node>
    <node id="97">
      <data key="d0">MOORE KUEHN, PLLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Moore Kuehn, PLLC is encouraging Abbott Laboratories investors to contact the law firm</data>
    </node>
    <node id="98">
      <data key="d0">HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">Hagens Berman, National Trial Attorneys is a law firm that specializes in national trial advocacy. The firm is currently involved in two separate legal actions, one against IonQ, Inc. (IONQ) and another against Abbott Laboratories.

Regarding the IonQ, Inc. case, Hagens Berman is encouraging investors who have experienced significant losses to contact the firm's attorneys before the August 1st deadline. The firm is pursuing a securities fraud action against IonQ, alleging that the company made false and misleading statements to investors.

In the case against Abbott Laboratories, Hagens Berman is also encouraging investors who have suffered significant losses to reach out to the firm's attorneys. The nature of the legal action against Abbott Laboratories is not specified in the provided information.

Hagens Berman is a well-known law firm that has a reputation for taking on high-profile cases and achieving successful outcomes for its clients. The firm's attorneys are experienced in handling complex litigation, including securities fraud cases and other matters involving publicly traded companies.

By encouraging investors to contact the firm, Hagens Berman is likely seeking to build a strong case against the respective companies and to potentially recover losses on behalf of its clients. The firm's involvement in these cases suggests that it believes there is a strong legal basis for the actions and that it is confident in its ability to achieve favorable results for the affected investors.

Overall, Hagens Berman, National Trial Attorneys is actively pursuing legal actions against IonQ, Inc. and Abbott Laboratories, and is encouraging investors who have experienced significant losses to come forward and join the firm's efforts.</data>
    </node>
    <node id="99">
      <data key="d0">OCTOBER 31, 2022</data>
      <data key="d1">EVENT</data>
      <data key="d2">0.0</data>
      <data key="d5">The deadline for investors to file a lead plaintiff motion in the securities class action lawsuit against Abbott Laboratories</data>
    </node>
    <node id="100">
      <data key="d0">HAGENS BERMAN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Hagens Berman is a national trial attorneys firm that is actively involved in representing investors in class action lawsuits against two major companies: IonQ and Abbott Laboratories.

Regarding IonQ, Hagens Berman is representing investors in a securities class action lawsuit. The firm is encouraging IonQ investors who have experienced significant losses to contact their attorneys to join the class action. Hagens Berman is serving as the legal counsel for these IonQ investors, seeking to recover their losses through the class action lawsuit.

In the case of Abbott Laboratories, Hagens Berman has filed a securities class action lawsuit against the company related to its infant formula products. The firm is representing investors in this class action, alleging that Abbott Laboratories made false and misleading statements about the safety and quality of its infant formula, which ultimately led to significant losses for investors. Hagens Berman is urging Abbott Laboratories investors who have suffered substantial losses to reach out to the firm's attorneys to participate in the class action lawsuit.

Overall, Hagens Berman is a national trial attorneys firm that is actively engaged in representing the interests of investors in high-profile class action lawsuits against major corporations. The firm is seeking to recover losses for investors who have been impacted by alleged corporate misconduct or misrepresentations. By consolidating the claims of individual investors into class actions, Hagens Berman aims to leverage its legal expertise and resources to achieve favorable outcomes for its clients.</data>
    </node>
    <node id="101">
      <data key="d0">ROSEN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Rosen is a law firm that is actively encouraging investors of two different companies, Abbott Laboratories and IonQ, to secure legal counsel before important deadlines in ongoing securities class action lawsuits.

Regarding Abbott Laboratories, Rosen is urging the company's investors to seek legal representation before an unspecified but important deadline in a securities class action. The law firm is advising Abbott Laboratories investors to take this step to protect their interests in the ongoing legal proceedings.

Similarly, Rosen is encouraging IonQ investors to secure counsel before the August 1 deadline in a securities class action involving the company. The law firm is specifically targeting IonQ investors who have experienced losses over $100,000, advising them to retain legal representation before this critical date.

While the details of the specific cases against Abbott Laboratories and IonQ are not provided, it is clear that Rosen, as a law firm, is actively soliciting clients who may have been impacted by alleged securities-related issues at these two companies. The firm is positioning itself as a resource for investors seeking to navigate the legal complexities and deadlines associated with these class action lawsuits.

By consolidating the information from the various descriptions, it appears that Rosen is taking a proactive approach in reaching out to investors of both Abbott Laboratories and IonQ, urging them to secure legal counsel before important deadlines in the respective securities class action proceedings. The law firm is likely seeking to represent these investors and help them pursue any potential claims or recoveries related to the alleged securities-related issues at the two companies.</data>
    </node>
    <node id="102">
      <data key="d0">INVESTOR COUNSEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Investor Counsel is an organization that is encouraging Abbott Laboratories investors to secure counsel before an important deadline in the securities class action lawsuit</data>
    </node>
    <node id="103">
      <data key="d0">THE LAW OFFICES OF VINCENT WONG</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">The Law Offices of Vincent Wong is a law firm that has notified investors of multiple class action lawsuits. According to the provided descriptions, the firm is currently involved in a class action lawsuit against IonQ, Inc., a quantum computing company.

The Law Offices of Vincent Wong are notifying investors of the IonQ class action lawsuit. The firm is informing investors about this legal action, which appears to be related to the company's business and financial practices. The descriptions indicate that the law firm is representing investors in this class action lawsuit against IonQ.

However, the provided information also includes a contradictory statement that the Law Offices of Vincent Wong is notifying investors of a class action lawsuit involving Abbott Laboratories, a healthcare company. This suggests that the law firm may be involved in multiple class action lawsuits, not just the one against IonQ.

To summarize, the Law Offices of Vincent Wong is a law firm that is currently representing investors in a class action lawsuit against IonQ, Inc., a quantum computing company. The firm is notifying investors about this legal action and their involvement in the case. While the descriptions primarily focus on the IonQ lawsuit, there is also a mention of the firm being involved in a class action lawsuit against Abbott Laboratories, though the details of this case are not provided.

It is important to note that the information provided does not include the specific details or allegations of the class action lawsuits, such as the nature of the claims, the timeline of events, or the potential outcomes. The summary is based solely on the limited descriptions given in the data.</data>
    </node>
    <node id="104">
      <data key="d0">THE KLEIN LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">The Klein Law Firm is a law firm that is currently involved in two separate class action lawsuits. 

Firstly, the firm has announced a lead plaintiff deadline of August 1, 2022 in a class action lawsuit filed on behalf of IonQ, Inc. limited shareholders. The Klein Law Firm is representing IonQ shareholders in this class action lawsuit.

Secondly, the firm is also announcing a lead plaintiff deadline of October 31, 2022 in a class action lawsuit filed against Abbott Laboratories. This suggests that the Klein Law Firm is representing shareholders of Abbott Laboratories in this separate class action.

The details provided indicate that the Klein Law Firm is actively pursuing legal action on behalf of shareholders for both IonQ, Inc. and Abbott Laboratories. The firm is seeking to establish a lead plaintiff in each of these class action lawsuits, with the deadlines being August 1, 2022 for the IonQ case and October 31, 2022 for the Abbott Laboratories case.

Overall, the Klein Law Firm appears to be taking on significant legal matters related to potential shareholder grievances against these two publicly traded companies. The firm is working to represent the interests of shareholders in these class action proceedings, with the goal of achieving favorable outcomes for their clients.</data>
    </node>
    <node id="105">
      <data key="d0">KEHOE LAW FIRM, P.C.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Kehoe Law Firm, P.C. is encouraging Abbott Laboratories shareholders to contact them to discuss potential legal claims</data>
    </node>
    <node id="106">
      <data key="d0">JAKUBOWITZ LAW</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Jakubowitz Law is pursuing claims on behalf of Abbott Laboratories shareholders</data>
    </node>
    <node id="107">
      <data key="d0">THE GROSS LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">The Gross Law Firm is a legal practice that is currently involved in two separate class action lawsuits on behalf of shareholders.

Firstly, The Gross Law Firm is notifying shareholders of Abbott Laboratories of a class action lawsuit and a lead plaintiff deadline of October 31, 2022. This lawsuit is related to the company's operations and financial reporting. The Gross Law Firm is representing shareholders in this case and is seeking to establish a lead plaintiff to represent the class.

Secondly, The Gross Law Firm is also notifying shareholders of a class action lawsuit against IonQ. IonQ is a quantum computing company, and the lawsuit appears to be related to the company's business activities and disclosures to shareholders. The Gross Law Firm is representing the interests of IonQ shareholders in this case as well.

While the specific details of the two lawsuits are not provided, it is clear that The Gross Law Firm is actively engaged in litigation on behalf of shareholders of both Abbott Laboratories and IonQ. The firm is taking on these cases to protect the rights and interests of the respective shareholders, and is working to establish lead plaintiffs to represent the broader class of affected investors.

The Gross Law Firm's involvement in these class action lawsuits demonstrates its commitment to holding companies accountable for their actions and ensuring that shareholders are fairly represented. The firm's willingness to take on these complex legal battles is a testament to its expertise and dedication to advocating for the rights of its clients.

Overall, The Gross Law Firm appears to be a reputable and experienced legal practice that is actively engaged in protecting the interests of shareholders through its involvement in these two class action lawsuits. The firm's efforts to notify shareholders and establish lead plaintiffs in these cases are an important step in the legal process, and the outcomes of these lawsuits may have significant implications for the companies and their shareholders.</data>
    </node>
    <node id="108">
      <data key="d0">THE SCHALL LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">The Schall Law Firm is a law firm that is actively involved in representing investors in class action lawsuits against two different companies: IonQ, Inc. and Abbott Laboratories.

Regarding IonQ, Inc., the Schall Law Firm is encouraging investors who have experienced losses of $100,000 or more to contact the firm. The firm is representing these investors in a class action lawsuit against IonQ. The Schall Law Firm is seeking to recover damages for IonQ investors who have suffered significant financial losses.

Similarly, the Schall Law Firm is also representing investors in a class action lawsuit against Abbott Laboratories. The firm is encouraging investors in Abbott Laboratories who have experienced losses of $100,000 or more to reach out to them regarding this class action.

While the descriptions provided do not explicitly state the reasons for the class action lawsuits against IonQ and Abbott Laboratories, it can be inferred that the Schall Law Firm believes there are grounds for these legal actions. The firm is actively seeking to represent investors who have suffered substantial financial losses in these cases.

It is important to note that the descriptions provided do not contain any contradictory information. The Schall Law Firm's involvement in these class action lawsuits appears to be consistent across the different descriptions.

In summary, the Schall Law Firm is a law firm that is currently representing investors in class action lawsuits against two companies: IonQ, Inc. and Abbott Laboratories. The firm is encouraging investors who have experienced significant losses (over $100,000) to contact them regarding these legal proceedings.</data>
    </node>
    <node id="109">
      <data key="d0">ROSEN LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">The Rosen Law Firm is a legal practice that specializes in representing investors in class action lawsuits. The firm is currently involved in two notable cases:

1. Abbott Laboratories Class Action Lawsuit: The Rosen Law Firm is representing investors in a class action lawsuit against Abbott Laboratories. The lawsuit alleges that the company made false and misleading statements regarding its financial performance and the safety of its products, which ultimately led to significant losses for investors.

2. IonQ Securities Class Action: The Rosen Law Firm is also encouraging investors in IonQ, a quantum computing company, to secure legal counsel before an important deadline in a securities class action lawsuit. The firm believes that IonQ may have made false or misleading statements about its business and technology, resulting in investor losses.

The Rosen Law Firm has a track record of successfully representing investors in complex class action lawsuits. The firm's attorneys have extensive experience in securities litigation and are dedicated to protecting the rights of investors. They work tirelessly to ensure that their clients receive the compensation they are entitled to, whether through settlements or court rulings.

In the case of the Abbott Laboratories lawsuit, the Rosen Law Firm is alleging that the company's management made false and misleading statements about the company's financial performance and the safety of its products. These alleged misrepresentations are said to have artificially inflated the company's stock price, leading to significant losses for investors when the truth was eventually revealed.

Similarly, in the IonQ case, the Rosen Law Firm believes that the company may have made false or misleading statements about its business and technology, which could have resulted in investor losses. The firm is encouraging IonQ investors to secure legal counsel before an important deadline in the securities class action lawsuit, as they may be eligible for compensation.

Overall, the Rosen Law Firm is a respected and experienced legal practice that is dedicated to protecting the rights of investors. The firm's involvement in these high-profile class action lawsuits demonstrates its commitment to holding companies accountable for their actions and ensuring that investors are fairly compensated for their losses.</data>
    </node>
    <node id="110">
      <data key="d0">RIGRODSKY LAW, P.A.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">0.0</data>
      <data key="d5">Rigrodsky Law, P.A. is investigating the class action lawsuit against Abbott Laboratories</data>
    </node>
    <node id="111">
      <data key="d0">ALTIMMUNE, INC.</data>
      <data key="d1" />
      <data key="d2">19.0</data>
      <data key="d5" />
    </node>
    <node id="112">
      <data key="d0">IMPACT PHASE 2B MASH TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">19.0</data>
      <data key="d5">The IMPACT Phase 2b MASH trial was a clinical trial conducted by Altimmune to evaluate the drug Pemvidutide for the treatment of MASH</data>
    </node>
    <node id="113">
      <data key="d0">PEMVIDUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">19.0</data>
      <data key="d5">Pemvidutide is a drug developed by Altimmune that was evaluated in the IMPACT Phase 2b MASH trial</data>
    </node>
    <node id="114">
      <data key="d0">CHRISTOPHER MONROE</data>
      <data key="d1">PERSON</data>
      <data key="d2">15.0</data>
      <data key="d5">Christopher Monroe is a co-founder of IonQ, Inc.</data>
    </node>
    <node id="115">
      <data key="d0">JUNG SANG KIM</data>
      <data key="d1">PERSON</data>
      <data key="d2">15.0</data>
      <data key="d5">Jung Sang Kim is a co-founder of IonQ, Inc.</data>
    </node>
    <node id="116">
      <data key="d0">COLLEGE PARK</data>
      <data key="d1">GEO</data>
      <data key="d2">15.0</data>
      <data key="d5">College Park, MD is the headquarters location of IonQ, Inc.</data>
    </node>
    <node id="117">
      <data key="d0">IONQ</data>
      <data key="d1" />
      <data key="d2">15.0</data>
      <data key="d5" />
    </node>
    <node id="118">
      <data key="d0">SKYWATER TECHNOLOGY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">SkyWater Technology is a company that IonQ is acquiring to build a vertically integrated quantum platform.</data>
    </node>
    <node id="119">
      <data key="d0">SKYWATER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">SkyWater Technology is a company being acquired by IonQ, as mentioned in the text</data>
    </node>
    <node id="120">
      <data key="d0">KATIE ARRINGTON</data>
      <data key="d1">PERSON</data>
      <data key="d2">15.0</data>
      <data key="d5">Katie Arrington was named CIO of IonQ</data>
    </node>
    <node id="121">
      <data key="d0">LESLIE KERSHAW</data>
      <data key="d1">PERSON</data>
      <data key="d2">15.0</data>
      <data key="d5">Leslie Kershaw was named CISO of IonQ</data>
    </node>
    <node id="122">
      <data key="d0">QBTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">10.0</data>
      <data key="d5">QBTS is a quantum computing company mentioned in the text</data>
    </node>
    <node id="123">
      <data key="d0">RGTI</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">10.0</data>
      <data key="d5">RGTI is a quantum computing company mentioned in the text</data>
    </node>
    <node id="124">
      <data key="d0">QUBT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">10.0</data>
      <data key="d5">QUBT is a quantum computing company mentioned in the text</data>
    </node>
    <node id="125">
      <data key="d0">KLEIN LAW FIRM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">The Klein Law Firm is a law firm representing IonQ investors</data>
    </node>
    <node id="126">
      <data key="d0">VINCENT WONG</data>
      <data key="d1">PERSON</data>
      <data key="d2">15.0</data>
      <data key="d5">Vincent Wong is a lawyer representing IonQ investors</data>
    </node>
    <node id="127">
      <data key="d0">SCHALL LAW FIRM</data>
      <data key="d1" />
      <data key="d2">15.0</data>
      <data key="d5" />
    </node>
    <node id="128">
      <data key="d0">BRONSTEIN, GEWIRTZ &amp; GROSSMAN, LLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Bronstein, Gewirtz &amp; Grossman is a law firm reminding IonQ investors of the upcoming class action deadline</data>
    </node>
    <node id="129">
      <data key="d0">AUGUST 1</data>
      <data key="d1">EVENT</data>
      <data key="d2">15.0</data>
      <data key="d5">The lead plaintiff deadline for the class action lawsuit against IonQ is August 1, 2022</data>
    </node>
    <node id="130">
      <data key="d0">IONQ, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">IonQ, Inc. is a company that has been the subject of a class action lawsuit. According to the information provided, IonQ, Inc. was mentioned in relation to Levi &amp; Korsinsky's class action litigation work.

The details surrounding the class action lawsuit against IonQ, Inc. are not entirely clear from the given information. However, it appears that the company has been involved in some form of legal dispute or litigation, which has led to a class action lawsuit being filed against it.

Class action lawsuits are legal proceedings where a group of individuals or entities with similar grievances come together to file a lawsuit against a common defendant. These types of lawsuits are often used to address large-scale issues or widespread harm caused by a company's actions or inactions.

While the specific nature of the allegations or claims made against IonQ, Inc. in the class action lawsuit are not provided, the fact that the company has been named as a defendant suggests that there may have been some concerns or issues with the company's operations, practices, or disclosures that have led to legal action being taken against it.

It is important to note that the information provided is limited, and the outcome or current status of the class action lawsuit against IonQ, Inc. is not known. The company may have addressed the issues raised in the lawsuit, or the litigation may still be ongoing.

In summary, IonQ, Inc. is a company that has been the subject of a class action lawsuit, as indicated by the information provided. The specific details and nature of the lawsuit are not fully clear, but the company's involvement in such legal proceedings suggests that there may have been concerns or issues related to its operations or practices that have led to this legal action.</data>
    </node>
    <node id="131">
      <data key="d0">AUGUST 1, 2022</data>
      <data key="d1">EVENT</data>
      <data key="d2">14.0</data>
      <data key="d5">The lead plaintiff deadline for the IonQ class action lawsuit is August 1, 2022</data>
    </node>
    <node id="132">
      <data key="d0">COMPETITORS</data>
      <data key="d1" />
      <data key="d2">15.0</data>
      <data key="d5" />
    </node>
    <node id="133">
      <data key="d0">TOTAL REVENUE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Total revenue is a key financial metric for IonQ</data>
    </node>
    <node id="134">
      <data key="d0">NET INCOME</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Net income is a key financial metric for IonQ</data>
    </node>
    <node id="135">
      <data key="d0">EARNINGS PER SHARE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Earnings per share is a key financial metric for IonQ</data>
    </node>
    <node id="136">
      <data key="d0">NET PROFIT MARGIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Net profit margin is a key financial metric for IonQ</data>
    </node>
    <node id="137">
      <data key="d0">FREE CASH FLOW</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Free cash flow is a key financial metric for IonQ</data>
    </node>
    <node id="138">
      <data key="d0">DEBT-TO-EQUITY RATIO</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Debt-to-equity ratio is a key financial metric for IonQ</data>
    </node>
    <node id="139">
      <data key="d0">GLOBE NEWSWIRE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">The news wire service that published the announcement about the Vistagen Therapeutics lawsuit</data>
    </node>
    <node id="140">
      <data key="d0">LEVI KORSINSKY TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">A trial involving the law firm Levi &amp; Korsinsky</data>
    </node>
    <node id="141">
      <data key="d0">CAPRICOR THERAPEUTICS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Capricor Therapeutics is a public company that was the subject of a securities fraud class action lawsuit filed by Levi &amp; Korsinsky</data>
    </node>
    <node id="142">
      <data key="d0">ALTIMMUNE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Altimmune was a company that Levi &amp; Korsinsky reminded investors of a pending class action lawsuit against</data>
    </node>
    <node id="143">
      <data key="d0">CALIFORNIA FEDERAL JUDGE</data>
      <data key="d1">PERSON</data>
      <data key="d2">12.0</data>
      <data key="d5">A California federal judge disqualified Levi &amp; Korsinsky from serving as lead counsel in a proposed investor class action</data>
    </node>
    <node id="144">
      <data key="d0">CALIFORNIA</data>
      <data key="d1">GEO</data>
      <data key="d2">12.0</data>
      <data key="d5">California is the geographic location where the federal judge is based</data>
    </node>
    <node id="145">
      <data key="d0">KARI A. DOOLEY</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Kari A. Dooley is a United States District Judge who appointed Jason D. Smith as Lead Plaintiff and approved the selection of Levi &amp; Korsinsky, LLP as Lead Counsel</data>
    </node>
    <node id="146">
      <data key="d0">JASON D. SMITH</data>
      <data key="d1">PERSON</data>
      <data key="d2">20.0</data>
      <data key="d5">Jason D. Smith has been appointed as Lead Plaintiff in the Tronox Holdings PLC lawsuit</data>
    </node>
    <node id="147">
      <data key="d0">FEDERAL SECURITIES CLASS ACTION</data>
      <data key="d1">EVENT</data>
      <data key="d2">18.0</data>
      <data key="d5">The lawsuit against Tronox Holdings PLC is a federal securities class action</data>
    </node>
    <edge id="e0" source="0" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a class action securities lawsuit against Capricor Therapeutics, Inc. on behalf of shareholders who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.</data>
    </edge>
    <edge id="e1" source="0" target="2">
      <data key="d3">10.0</data>
      <data key="d4">sought Biologics License...</data>
      <data key="d6">Capricor Therapeutics, Inc. sought a Biologics License Application (BLA) from the FDA for its lead drug candidate deramiocel, but received a Complete Response Letter (CRL) from the FDA denying the BLA and citing the need for additional clinical data.</data>
    </edge>
    <edge id="e2" source="3" target="4">
      <data key="d3">19.0</data>
      <data key="d4">Muscular Dystrophy (DMD)...</data>
      <data key="d6">Deramiocel and Duchenne Muscular Dystrophy (DMD)

Deramiocel is Capricor Therapeutics' lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Deramiocel is being developed to treat the cardiomyopathy, or heart muscle disease, that often accompanies DMD, a rare and severe genetic disorder.

Duchenne muscular dystrophy (DMD) is a progressive and debilitating genetic condition that primarily affects young boys. It is characterized by the gradual weakening and breakdown of skeletal and cardiac muscles, leading to significant disability and, ultimately, premature death. The disease is caused by a mutation in the dystrophin gene, which is responsible for producing the protein dystrophin, essential for maintaining the structural integrity of muscle fibers.

As DMD progresses, the weakening of the heart muscle, or cardiomyopathy, becomes a major complication and a leading cause of mortality in individuals with the disease. Deramiocel, Capricor Therapeutics' cell therapy candidate, is being developed specifically to address this cardiac manifestation of DMD.

The development of Deramiocel is based on the use of cardiosphere-derived cells (CDCs), which are a type of stem cell isolated from the patient's own heart tissue. These cells have the potential to differentiate into various cardiac cell types, including cardiomyocytes, endothelial cells, and smooth muscle cells, and have shown the ability to improve cardiac function in preclinical studies.

The goal of Deramiocel is to restore cardiac function and prevent or slow the progression of cardiomyopathy in individuals with DMD. By delivering these regenerative cells to the heart, Deramiocel aims to promote the repair and regeneration of damaged cardiac tissue, ultimately improving the overall cardiac health and quality of life for patients with DMD.

Capricor Therapeutics is currently conducting clinical trials to evaluate the safety and efficacy of Deramiocel in treating the cardiomyopathy associated with DMD. The company's efforts to develop this innovative cell therapy highlight the ongoing research and progress being made in addressing the complex and devastating effects of this rare genetic disorder.</data>
    </edge>
    <edge id="e3" source="5" target="9">
      <data key="d3">18.0</data>
      <data key="d4">LLP filed class...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP filed a class action lawsuit against Vistagen Therapeutics, Inc. related to its PALISADE-3 clinical trial</data>
    </edge>
    <edge id="e4" source="5" target="6">
      <data key="d3">50.0</data>
      <data key="d4">LLP law firm...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP is a law firm that specializes in representing investors in class action lawsuits. Joseph E. Levi is an attorney at Levi &amp; Korsinsky, LLP who is leading several investigations and lawsuits on behalf of investors.

According to the provided descriptions, Joseph E. Levi is involved in the following cases:

1. Alector, Inc.: Levi is leading the investigation into Alector, Inc., a biotechnology company, on behalf of investors.

2. Altimmune: Levi is representing investors in a lawsuit against Altimmune, a biopharmaceutical company.

3. Vistagen Therapeutics, Inc.: Levi is involved in a class action lawsuit against Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company.

The descriptions do not provide any contradictory information about Joseph E. Levi's involvement in these cases. He appears to be an experienced attorney at Levi &amp; Korsinsky, LLP who is actively representing investors in various lawsuits against biotechnology and biopharmaceutical companies.

Levi &amp; Korsinsky, LLP is a law firm that has a track record of successfully representing investors in class action lawsuits. The firm's attorneys, including Joseph E. Levi, have extensive experience in investigating and litigating cases related to securities fraud, corporate governance, and other investor-related issues.

In the case of Alector, Inc., Levi is leading the investigation on behalf of investors, suggesting that the firm has identified potential issues or concerns with the company's practices or disclosures that may have negatively impacted investors.

Similarly, in the Altimmune and Vistagen Therapeutics, Inc. cases, Levi is representing investors in class action lawsuits, indicating that the firm believes there are grounds for legal action against these companies.

Overall, the provided information suggests that Joseph E. Levi and Levi &amp; Korsinsky, LLP are actively engaged in protecting the interests of investors by investigating and pursuing legal action against companies that may have engaged in wrongdoing or made misleading statements that have harmed investors.</data>
    </edge>
    <edge id="e5" source="5" target="7">
      <data key="d3">35.0</data>
      <data key="d4">LLP law firm...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP is a law firm that specializes in representing investors in class action lawsuits. Ed Korsinsky is an attorney at Levi &amp; Korsinsky who is actively involved in several high-profile cases.

One of the cases that Ed Korsinsky is leading is an investigation into Alector, Inc., a biotechnology company. Korsinsky is representing investors in this investigation, which is likely related to potential issues or concerns with Alector's business or financial practices.

In addition to the Alector case, Korsinsky is also representing investors in a lawsuit against Altimmune, another biotechnology company. The nature of the lawsuit against Altimmune is not specified in the provided information, but it is clear that Korsinsky is playing a key role in this legal action on behalf of Altimmune investors.

Furthermore, Korsinsky is involved in a class action lawsuit against Vistagen Therapeutics, Inc., a biopharmaceutical company. The details of this lawsuit are also not provided, but it is evident that Korsinsky is actively engaged in this legal proceeding as well.

Overall, Ed Korsinsky, as an attorney at Levi &amp; Korsinsky, LLP, is actively involved in multiple high-profile legal cases, primarily focused on representing investors in the biotechnology and pharmaceutical industries. The firm's expertise in class action lawsuits and its willingness to take on complex cases against larger companies suggest that Levi &amp; Korsinsky, LLP is a prominent player in the field of investor protection and corporate accountability.</data>
    </edge>
    <edge id="e6" source="8" target="9">
      <data key="d3">10.0</data>
      <data key="d4">conducted PALISADE-3 Phase...</data>
      <data key="d6">Vistagen Therapeutics, Inc. conducted the PALISADE-3 Phase 3 clinical trial for its investigational drug fasedienol</data>
    </edge>
    <edge id="e7" source="11" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against the University of Florida's official website for alleged violations of the VPPA</data>
    </edge>
    <edge id="e8" source="12" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against the University of Texas's official website for alleged violations of the VPPA</data>
    </edge>
    <edge id="e9" source="13" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against the University of Nebraska's official website for alleged violations of the VPPA</data>
    </edge>
    <edge id="e10" source="14" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against the University of Southern California (USC)'s official website for alleged violations of the VPPA and for the use of Google's Programmable Search Engine</data>
    </edge>
    <edge id="e11" source="15" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed class action lawsuits against the college athletic program websites managed by Learfield for alleged privacy violations</data>
    </edge>
    <edge id="e12" source="16" target="5">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed class action lawsuits against the college athletic program websites managed by Sidearm Sports, a Learfield subsidiary, for alleged privacy violations</data>
    </edge>
    <edge id="e13" source="17" target="5">
      <data key="d3">16.0</data>
      <data key="d4">alleged that use...</data>
      <data key="d6">Levi &amp; Korsinsky alleged that the use of Meta's Facebook Pixel tracking technology on the college athletic program websites without proper user consent led to the class action lawsuits</data>
    </edge>
    <edge id="e14" source="18" target="5">
      <data key="d3">2.0</data>
      <data key="d4">alleged that use...</data>
      <data key="d6">Levi &amp; Korsinsky alleged that the use of Google's Programmable Search Engine technology on the University of Southern California (USC) website without proper user consent led to the class action lawsuit</data>
    </edge>
    <edge id="e15" source="19" target="1">
      <data key="d3">16.0</data>
      <data key="d4">consumer protection team...</data>
      <data key="d6">Levi &amp; Korsinsky's consumer protection team targets companies for various consumer protection issues, including data breaches</data>
    </edge>
    <edge id="e16" source="20" target="1">
      <data key="d3">18.0</data>
      <data key="d4">appointed lead counsel...</data>
      <data key="d6">Levi &amp; Korsinsky was appointed lead counsel in the class action lawsuit against Xerox Holdings in 2025</data>
    </edge>
    <edge id="e17" source="21" target="1">
      <data key="d3">18.0</data>
      <data key="d4">appointed lead counsel...</data>
      <data key="d6">Levi &amp; Korsinsky was appointed lead counsel in the consolidated securities fraud actions against DZS Inc. in 2024</data>
    </edge>
    <edge id="e18" source="22" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against Lilium N.V. in 2024, alleging overstated fundraising progress and failure to disclose insolvency risks</data>
    </edge>
    <edge id="e19" source="23" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against iLearningEngines, Inc. in 2024, alleging the company overstated revenue using a related party to report "largely fake" financials</data>
    </edge>
    <edge id="e20" source="24" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against Iris Energy Limited in 2024, alleging the company overstated its data center and high-performance computing prospects due to deficiencies at its Childress County, Texas site</data>
    </edge>
    <edge id="e21" source="25" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against Cerevel Therapeutics Holdings, Inc. in 2025, alleging misleading statements related to a merger with AbbVie Inc.</data>
    </edge>
    <edge id="e22" source="26" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against Viatris Inc. in 2025, alleging the company downplayed the impact of a warning letter and import alert affecting its Indore facility</data>
    </edge>
    <edge id="e23" source="27" target="1">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against The Southern Company in 2022, alleging misleading statements in audits of the company's financials, particularly regarding its Kemper, Mississippi "clean coal" plant</data>
    </edge>
    <edge id="e24" source="28" target="1">
      <data key="d3">16.0</data>
      <data key="d4">LLP defendant...</data>
      <data key="d6">Deloitte &amp; Touche, LLP was a defendant in the class action lawsuit against The Southern Company led by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e25" source="29" target="1">
      <data key="d3">18.0</data>
      <data key="d4">secured settlement...</data>
      <data key="d6">Levi &amp; Korsinsky secured a settlement in a stockholder derivative suit related to PureCycle Technologies, Inc.'s polypropylene recycling processes in 2023</data>
    </edge>
    <edge id="e26" source="15" target="1">
      <data key="d3">14.0</data>
      <data key="d4">with improper tracking,...</data>
      <data key="d6">Learfield operates websites with improper tracking, leading to class action lawsuits by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e27" source="16" target="1">
      <data key="d3">14.0</data>
      <data key="d4">websites with improper...</data>
      <data key="d6">Sidearm Sports operates websites with improper tracking, leading to class action lawsuits by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e28" source="14" target="1">
      <data key="d3">14.0</data>
      <data key="d4">website with improper...</data>
      <data key="d6">USC operated a website with improper tracking, leading to a class action lawsuit by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e29" source="11" target="1">
      <data key="d3">14.0</data>
      <data key="d4">Florida operated website...</data>
      <data key="d6">The University of Florida operated a website with improper tracking, leading to a class action lawsuit by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e30" source="17" target="1">
      <data key="d3">14.0</data>
      <data key="d4">Facebook Pixel, have...</data>
      <data key="d6">Meta's tools, such as the Facebook Pixel, have been implicated in class action lawsuits led by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e31" source="18" target="1">
      <data key="d3">14.0</data>
      <data key="d4">Programmable Search Engine,...</data>
      <data key="d6">Google's tools, such as the Programmable Search Engine, have been implicated in class action lawsuits led by Levi &amp; Korsinsky</data>
    </edge>
    <edge id="e32" source="30" target="1">
      <data key="d3">16.0</data>
      <data key="d4">were named defendants...</data>
      <data key="d6">Align Technology's executives were named as defendants in a class action lawsuit led by Levi &amp; Korsinsky in 2018</data>
    </edge>
    <edge id="e33" source="31" target="1">
      <data key="d3">2.0</data>
      <data key="d4">were named defendants...</data>
      <data key="d6">Transocean Ltd.'s executives were named as defendants in a class action lawsuit led by Levi &amp; Korsinsky in 2023</data>
    </edge>
    <edge id="e34" source="1" target="32">
      <data key="d3">14.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a securities class action against Lilium</data>
    </edge>
    <edge id="e35" source="1" target="33">
      <data key="d3">14.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a securities class action against iLearningEngines</data>
    </edge>
    <edge id="e36" source="1" target="34">
      <data key="d3">14.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a securities class action against Xerox</data>
    </edge>
    <edge id="e37" source="1" target="35">
      <data key="d3">14.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a securities class action against Viatris</data>
    </edge>
    <edge id="e38" source="1" target="16">
      <data key="d3">16.0</data>
      <data key="d4">filed privacy lawsuits...</data>
      <data key="d6">Levi &amp; Korsinsky has filed privacy lawsuits against Sidearm Sports-managed college websites</data>
    </edge>
    <edge id="e39" source="1" target="36">
      <data key="d3">14.0</data>
      <data key="d4">filed recent securities...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a recent securities class action against Iris Energy</data>
    </edge>
    <edge id="e40" source="1" target="37">
      <data key="d3">2.0</data>
      <data key="d4">been appointed lead...</data>
      <data key="d6">Levi &amp; Korsinsky has been appointed as lead counsel in a securities case against DZS</data>
    </edge>
    <edge id="e41" source="5" target="0">
      <data key="d3">9.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a class action lawsuit against Capricor Therapeutics on behalf of investors who were adversely affected by alleged securities fraud</data>
    </edge>
    <edge id="e42" source="38" target="0">
      <data key="d3">22.0</data>
      <data key="d4">Capricor Therapeutics, Inc....</data>
      <data key="d6">The HOPE-2 Trial and Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of cardiovascular and other serious medical conditions. The company conducted the Phase 2 HOPE-2 clinical trial to evaluate the safety and efficacy of deramiocel, an investigational therapy.

The HOPE-2 trial was a Phase 2 clinical trial conducted by Capricor Therapeutics to evaluate the safety and efficacy of deramiocel. Deramiocel is a cell therapy product derived from allogeneic cardiosphere-derived cells (CDCs), which are isolated from the patient's own heart tissue. The trial was designed to assess the potential of deramiocel to improve cardiac function and clinical outcomes in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.

DMD is a rare and devastating genetic disorder that primarily affects boys, causing progressive muscle weakness and degeneration. Cardiomyopathy, or weakening of the heart muscle, is a common and life-threatening complication of DMD, often leading to heart failure and premature death. The HOPE-2 trial aimed to evaluate whether deramiocel, with its potential to regenerate and repair damaged heart tissue, could improve cardiac function and clinical outcomes in these patients.

The trial enrolled patients with DMD-associated cardiomyopathy and randomized them to receive either deramiocel or a placebo. The primary endpoint of the study was the change in left ventricular ejection fraction (LVEF), a measure of the heart's pumping ability, at 12 months. Secondary endpoints included other measures of cardiac function, as well as assessments of physical function and quality of life.

The results of the HOPE-2 trial are eagerly awaited, as they will provide important insights into the potential of deramiocel as a novel therapeutic approach for the management of DMD-associated cardiomyopathy. If the trial demonstrates the safety and efficacy of deramiocel, it could represent a significant advancement in the treatment of this devastating condition, offering hope to patients and their families.

In summary, the HOPE-2 Trial, conducted by Capricor Therapeutics, Inc., is a Phase 2 clinical study evaluating the safety and efficacy of deramiocel, a cell therapy product, in patients with Duchenne muscular dystrophy-associated cardiomyopathy. The trial aims to assess the potential of deramiocel to improve cardiac function and clinical outcomes in this patient population, with the goal of providing a new therapeutic option for this devastating condition.</data>
    </edge>
    <edge id="e43" source="0" target="3">
      <data key="d3">18.0</data>
      <data key="d4">developing deramiocel cell...</data>
      <data key="d6">Capricor Therapeutics is developing deramiocel as a cell therapy drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD)</data>
    </edge>
    <edge id="e44" source="0" target="39">
      <data key="d3">16.0</data>
      <data key="d4">Capricor's Biologics License...</data>
      <data key="d6">The FDA denied Capricor's Biologics License Application (BLA) for deramiocel, citing a lack of substantial evidence of effectiveness and the need for additional clinical data</data>
    </edge>
    <edge id="e45" source="0" target="40">
      <data key="d3">8.0</data>
      <data key="d4">Biologics License Application...</data>
      <data key="d6">Capricor Therapeutics submitted a Biologics License Application (BLA) for deramiocel to the FDA, which was denied</data>
    </edge>
    <edge id="e46" source="39" target="41">
      <data key="d3">1.0</data>
      <data key="d4">Complete Response Letter...</data>
      <data key="d6">The FDA issued a Complete Response Letter (CRL) to Capricor Therapeutics, denying the Biologics License Application (BLA) for deramiocel</data>
    </edge>
    <edge id="e47" source="17" target="45">
      <data key="d3">3.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to Meta's stock performance.</data>
    </edge>
    <edge id="e48" source="10" target="45">
      <data key="d3">3.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to Microsoft's stock performance.</data>
    </edge>
    <edge id="e49" source="42" target="45">
      <data key="d3">3.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to NVIDIA's stock performance.</data>
    </edge>
    <edge id="e50" source="43" target="45">
      <data key="d3">3.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to Oracle's stock performance.</data>
    </edge>
    <edge id="e51" source="44" target="45">
      <data key="d3">1.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to Tesla's stock performance.</data>
    </edge>
    <edge id="e52" source="45" target="18">
      <data key="d3">3.0</data>
      <data key="d4">quote news APIs,...</data>
      <data key="d6">CloudQuote.io provides stock quote and news APIs, which may include data related to Google's stock performance.</data>
    </edge>
    <edge id="e53" source="45" target="47">
      <data key="d3">1.0</data>
      <data key="d4">service provided FinancialContent....</data>
      <data key="d6">CloudQuote.io is a service provided by FinancialContent.</data>
    </edge>
    <edge id="e54" source="18" target="46">
      <data key="d3">5.0</data>
      <data key="d4">stock ticker symbol...</data>
      <data key="d6">GOOG is the stock ticker symbol for the Google organization.</data>
    </edge>
    <edge id="e55" source="9" target="1">
      <data key="d3">63.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that has been the subject of a securities class action lawsuit filed by the law firm LEVI &amp; KORSINSKY. According to the multiple descriptions provided, Levi &amp; Korsinsky has filed this securities class action lawsuit against Vistagen Therapeutics on behalf of its shareholders.

The lawsuit appears to allege that Vistagen Therapeutics has committed securities violations, though the specific details of the alleged violations are not provided in the given information. The lawsuit has been filed on behalf of Vistagen Therapeutics' shareholders, indicating that the shareholders may have suffered losses or damages related to their investments in the company.

While the descriptions provided are consistent in stating that Levi &amp; Korsinsky has filed a securities class action lawsuit against Vistagen Therapeutics on behalf of its shareholders, there are no contradictions or conflicting information in the data. The descriptions all convey the same core facts about the lawsuit.

In summary, VISTAGEN THERAPEUTICS, INC., a biopharmaceutical company, is facing a securities class action lawsuit filed by the law firm LEVI &amp; KORSINSKY. The lawsuit has been brought on behalf of Vistagen Therapeutics' shareholders, though the specific allegations and details of the case are not provided in the given information.</data>
    </edge>
    <edge id="e56" source="9" target="8">
      <data key="d3">52.0</data>
      <data key="d4">biopharmaceutical company that...</data>
      <data key="d6">VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that was conducting the PALISADE-3 Phase 3 clinical trial study of its drug candidate fasedienol. The PALISADE-3 Phase 3 trial was a clinical study of Vistagen's drug fasedienol, which was being evaluated for the treatment of social anxiety disorder.

The PALISADE-3 Phase 3 trial was a key clinical study for Vistagen Therapeutics, as the company was focused on developing fasedienol as a potential treatment for social anxiety disorder. The trial was designed to assess the safety and efficacy of fasedienol in patients with social anxiety disorder, with the goal of ultimately obtaining regulatory approval for the drug.

Throughout the PALISADE-3 trial, Vistagen Therapeutics closely monitored the progress and results of the study, working to ensure that the trial was conducted in a rigorous and scientifically sound manner. The company's commitment to the development of fasedienol underscores its dedication to addressing the significant unmet medical needs of individuals suffering from social anxiety disorder.

By conducting the PALISADE-3 Phase 3 trial, Vistagen Therapeutics aimed to gather the necessary data and evidence to support the potential approval and commercialization of fasedienol as a new treatment option for social anxiety disorder. The successful completion of this trial would be a crucial milestone for the company and could have a significant impact on the lives of those affected by this debilitating condition.</data>
    </edge>
    <edge id="e57" source="9" target="48">
      <data key="d3">11.0</data>
      <data key="d4">biopharmaceutical company that...</data>
      <data key="d6">Vistagen Therapeutics, Inc. is a biopharmaceutical company that has been developing Fasedienol, an investigational drug candidate for the treatment of social anxiety disorder. 

Fasedienol is Vistagen's investigational drug that was being evaluated in the PALISADE-3 clinical trial for the treatment of social anxiety disorder. The descriptions provided indicate that Fasedienol is an investigational drug candidate developed by Vistagen Therapeutics for this specific purpose.

Social anxiety disorder is a mental health condition characterized by intense fear or anxiety in social situations. Fasedienol was being studied as a potential treatment option for individuals suffering from this disorder.

The available information suggests that Vistagen Therapeutics was responsible for the development of Fasedienol and its evaluation in the PALISADE-3 clinical trial for the treatment of social anxiety disorder. There are no apparent contradictions in the provided descriptions.

In summary, Vistagen Therapeutics, Inc. is a biopharmaceutical company that has been developing Fasedienol, an investigational drug candidate, for the treatment of social anxiety disorder. Fasedienol was being evaluated in the PALISADE-3 clinical trial as a potential treatment option for individuals with social anxiety disorder.</data>
    </edge>
    <edge id="e58" source="6" target="1">
      <data key="d3">41.0</data>
      <data key="d4">is an attorney...</data>
      <data key="d6">Joseph E. Levi is an attorney at the law firm Levi &amp; Korsinsky. He represents Vistagen Therapeutics shareholders in legal matters.

Levi &amp; Korsinsky is a law firm that employs Joseph E. Levi as an attorney. The firm specializes in representing shareholders in legal disputes and class action lawsuits. As part of his work at Levi &amp; Korsinsky, Joseph E. Levi represents shareholders of Vistagen Therapeutics, a biopharmaceutical company focused on developing new treatments for central nervous system (CNS) disorders.

The provided descriptions do not contain any contradictory information about Joseph E. Levi or Levi &amp; Korsinsky. They consistently describe Joseph E. Levi as an attorney at the law firm Levi &amp; Korsinsky, and that he represents Vistagen Therapeutics shareholders as part of his work at the firm.

In summary, Joseph E. Levi is an attorney at the law firm Levi &amp; Korsinsky, where he represents Vistagen Therapeutics shareholders in legal matters. Levi &amp; Korsinsky is a law firm that specializes in shareholder representation and class action lawsuits.</data>
    </edge>
    <edge id="e59" source="7" target="1">
      <data key="d3">41.0</data>
      <data key="d4">attorney law...</data>
      <data key="d6">Ed Korsinsky is an attorney at the law firm Levi &amp; Korsinsky. He represents Vistagen Therapeutics shareholders in legal matters.

Levi &amp; Korsinsky is a law firm that employs Ed Korsinsky as an attorney. The firm specializes in representing shareholders in legal disputes and class action lawsuits. As part of his work at Levi &amp; Korsinsky, Ed Korsinsky represents shareholders of Vistagen Therapeutics, a biopharmaceutical company.

The provided descriptions do not contain any contradictory information about Ed Korsinsky or Levi &amp; Korsinsky. They consistently describe Ed Korsinsky as an attorney at the law firm Levi &amp; Korsinsky, and that he represents Vistagen Therapeutics shareholders as part of his work at the firm.

In summary, Ed Korsinsky is an attorney at the law firm Levi &amp; Korsinsky, where he represents Vistagen Therapeutics shareholders in legal matters. Levi &amp; Korsinsky is a law firm that specializes in shareholder representation and class action lawsuits.</data>
    </edge>
    <edge id="e60" source="49" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented QuantumScape...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented QuantumScape Corporation in a $47.5 million settlement</data>
    </edge>
    <edge id="e61" source="50" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Loma...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Loma Negra Industrial Argentina Sociedad Argentina in a $24.6 million settlement</data>
    </edge>
    <edge id="e62" source="51" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Corcept...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Corcept Therapeutics Incorporated in a $14 million settlement</data>
    </edge>
    <edge id="e63" source="52" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Babcock...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Babcock &amp; Wilcox Enterprises, Inc. in a $9.5 million settlement</data>
    </edge>
    <edge id="e64" source="53" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Steel...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented U.S. Steel in a $40 million settlement</data>
    </edge>
    <edge id="e65" source="54" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Aqua...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Aqua Metals, Inc. in a $7 million settlement</data>
    </edge>
    <edge id="e66" source="55" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented WideOpenWest,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented WideOpenWest, Inc. in a $7.025 million settlement</data>
    </edge>
    <edge id="e67" source="56" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Helios...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Helios and Matheson Analytics Inc. in an $8.25 million settlement</data>
    </edge>
    <edge id="e68" source="57" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Illumina,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Illumina, Inc. in a $13.85 million settlement</data>
    </edge>
    <edge id="e69" source="58" target="5">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Avon...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Avon Products Inc. in a $14.5 million settlement</data>
    </edge>
    <edge id="e70" source="59" target="5">
      <data key="d3">9.0</data>
      <data key="d4">praised handling...</data>
      <data key="d6">Ronald B. Rubin praised the handling of a case by Levi &amp; Korsinsky, LLP</data>
    </edge>
    <edge id="e71" source="60" target="5">
      <data key="d3">9.0</data>
      <data key="d4">praised conduct...</data>
      <data key="d6">Timothy S. Driscoll praised the conduct of the legal profession, including Levi &amp; Korsinsky, LLP</data>
    </edge>
    <edge id="e72" source="61" target="5">
      <data key="d3">9.0</data>
      <data key="d4">found Levi Korsinsky,...</data>
      <data key="d6">Andrew L. Carter, Jr. found Levi &amp; Korsinsky, LLP to be well-qualified to serve as Lead Counsel</data>
    </edge>
    <edge id="e73" source="62" target="5">
      <data key="d3">9.0</data>
      <data key="d4">Levi Korsinsky, LLP's...</data>
      <data key="d6">Analisa Torres noted Levi &amp; Korsinsky, LLP's "extensive experience" in securities litigation</data>
    </edge>
    <edge id="e74" source="63" target="5">
      <data key="d3">1.0</data>
      <data key="d4">found class counsel,...</data>
      <data key="d6">Barry Ted Moskowitz found the class counsel, including Levi &amp; Korsinsky, LLP, to be skilled and adequate to represent the settlement class</data>
    </edge>
    <edge id="e75" source="9" target="64">
      <data key="d3">9.0</data>
      <data key="d4">trial drug fasedienol...</data>
      <data key="d6">Vistagen's Phase 3 trial for its drug fasedienol did not meet the primary endpoint for treating social anxiety disorder</data>
    </edge>
    <edge id="e76" source="9" target="65">
      <data key="d3">8.0</data>
      <data key="d4">class action lawsuit...</data>
      <data key="d6">Deadline for filing class action lawsuit against Vistagen Therapeutics, Inc. is March 16 2026</data>
    </edge>
    <edge id="e77" source="67" target="5">
      <data key="d3">1.0</data>
      <data key="d4">serving lead counsel...</data>
      <data key="d6">Levi &amp; Korsinsky is serving as lead counsel in the Tronox Holdings PLC lawsuit</data>
    </edge>
    <edge id="e78" source="48" target="68">
      <data key="d3">1.0</data>
      <data key="d4">developed Vistagen Therapeutics...</data>
      <data key="d6">Fasedienol was being developed by Vistagen Therapeutics to treat social anxiety disorder</data>
    </edge>
    <edge id="e79" source="5" target="69">
      <data key="d3">16.0</data>
      <data key="d4">investigating Alector, Inc....</data>
      <data key="d6">Levi &amp; Korsinsky is investigating Alector, Inc. for possible securities law violations after Alector announced negative results from its Phase 2 clinical trial</data>
    </edge>
    <edge id="e80" source="69" target="70">
      <data key="d3">8.0</data>
      <data key="d4">drug developed Alector,...</data>
      <data key="d6">Latozinemab (AL001) is a drug developed by Alector, Inc. to treat frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </edge>
    <edge id="e81" source="70" target="71">
      <data key="d3">8.0</data>
      <data key="d4">being evaluated clinical...</data>
      <data key="d6">Latozinemab (AL001) was being evaluated in a clinical trial to treat frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </edge>
    <edge id="e82" source="72" target="74">
      <data key="d3">18.0</data>
      <data key="d4">founded Abbott Laboratories...</data>
      <data key="d6">Wallace Calvin Abbott founded Abbott Laboratories in 1888.</data>
    </edge>
    <edge id="e83" source="73" target="74">
      <data key="d3">9.0</data>
      <data key="d4">headquartered Abbott Park,...</data>
      <data key="d6">Abbott Laboratories is headquartered in Abbott Park, Illinois.</data>
    </edge>
    <edge id="e84" source="74" target="75">
      <data key="d3">8.0</data>
      <data key="d4">Products segment one...</data>
      <data key="d6">The Established Pharmaceutical Products segment is one of the four operating segments of Abbott Laboratories.</data>
    </edge>
    <edge id="e85" source="74" target="76">
      <data key="d3">8.0</data>
      <data key="d4">segment one...</data>
      <data key="d6">The Diagnostic Products segment is one of the four operating segments of Abbott Laboratories.</data>
    </edge>
    <edge id="e86" source="74" target="77">
      <data key="d3">8.0</data>
      <data key="d4">segment one...</data>
      <data key="d6">The Nutritional Products segment is one of the four operating segments of Abbott Laboratories.</data>
    </edge>
    <edge id="e87" source="74" target="78">
      <data key="d3">1.0</data>
      <data key="d4">segment one...</data>
      <data key="d6">The Medical Devices segment is one of the four operating segments of Abbott Laboratories.</data>
    </edge>
    <edge id="e88" source="79" target="74">
      <data key="d3">3.0</data>
      <data key="d4">Janux Therapeutics Inc...</data>
      <data key="d6">Abbott Laboratories and Janux Therapeutics Inc are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e89" source="80" target="74">
      <data key="d3">3.0</data>
      <data key="d4">BioCryst both healthcare...</data>
      <data key="d6">Abbott Laboratories and BioCryst are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e90" source="81" target="74">
      <data key="d3">3.0</data>
      <data key="d4">Exact Sciences both...</data>
      <data key="d6">Abbott Laboratories and Exact Sciences are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e91" source="82" target="74">
      <data key="d3">3.0</data>
      <data key="d4">Telix Pharmaceuticals both...</data>
      <data key="d6">Abbott Laboratories and Telix Pharmaceuticals are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e92" source="83" target="74">
      <data key="d3">3.0</data>
      <data key="d4">DexCom both healthcare...</data>
      <data key="d6">Abbott Laboratories and DexCom are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e93" source="84" target="74">
      <data key="d3">3.0</data>
      <data key="d4">Amgen both healthcare...</data>
      <data key="d6">Abbott Laboratories and Amgen are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e94" source="85" target="74">
      <data key="d3">3.0</data>
      <data key="d4">Annexon Biosciences both...</data>
      <data key="d6">Abbott Laboratories and Annexon Biosciences are both healthcare companies that were discussed by analysts</data>
    </edge>
    <edge id="e95" source="86" target="74">
      <data key="d3">72.0</data>
      <data key="d4">law firm, filed...</data>
      <data key="d6">Bernstein Liebhard LLP, a law firm, has filed a securities class action lawsuit against Abbott Laboratories, a major pharmaceutical and healthcare company. The lawsuit alleges that Abbott Laboratories made false and misleading statements regarding its infant formula business, which led to significant losses for investors.

According to the descriptions provided, Bernstein Liebhard LLP is representing investors and shareholders in this class action lawsuit against Abbott Laboratories. The firm is reminding investors of the deadline to file a lead plaintiff motion in the lawsuit, indicating that the legal proceedings are ongoing.

The lawsuit appears to be related to issues surrounding Abbott Laboratories' infant formula business. While the specific details of the allegations are not provided, it is clear that the lawsuit claims that the company made false or misleading statements that resulted in financial losses for investors.

Bernstein Liebhard LLP is a law firm that specializes in representing investors and shareholders in securities class action lawsuits. The firm is taking on this case against Abbott Laboratories, a large and well-known pharmaceutical and healthcare company, on behalf of its clients who have been affected by the alleged misconduct.

The descriptions indicate that the lawsuit is in the early stages, with the firm reminding investors of the deadline to file a lead plaintiff motion. This suggests that the case is still ongoing and that the firm is actively seeking to build a strong case on behalf of its clients.

Overall, the summary of the data provided suggests that Bernstein Liebhard LLP has filed a securities class action lawsuit against Abbott Laboratories, alleging that the company made false or misleading statements regarding its infant formula business, which resulted in financial losses for investors. The firm is representing investors and shareholders in this ongoing legal proceeding.</data>
    </edge>
    <edge id="e96" source="1" target="74">
      <data key="d3">74.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Levi &amp; Korsinsky, a law firm, is representing investors in a class action lawsuit against Abbott Laboratories, a major healthcare company. The lawsuit is related to alleged misconduct or issues at Abbott Laboratories that have impacted investors.

Levi &amp; Korsinsky is reminding Abbott Laboratories investors of the pending class action lawsuit, which has a lead plaintiff deadline of October 31, 2022. This suggests the lawsuit was recently filed and Levi &amp; Korsinsky is encouraging affected investors to join the class action before the deadline.

The descriptions indicate that Levi &amp; Korsinsky is representing shareholders in this class action lawsuit against Abbott Laboratories. Class action lawsuits allow a group of investors who have been impacted in a similar way to collectively seek damages or resolution from the company they are suing.

While the specific details of the allegations against Abbott Laboratories are not provided, the fact that Levi &amp; Korsinsky has filed a class action lawsuit suggests there are serious concerns about the company's actions or disclosures that have negatively affected its investors. Class action lawsuits are typically pursued when a company is accused of securities fraud, misrepresentation, or other misconduct that has financially harmed a large group of shareholders.

In summary, Levi &amp; Korsinsky, a law firm, is representing investors in a class action lawsuit against Abbott Laboratories. The lawsuit has a lead plaintiff deadline of October 31, 2022, and appears to be related to alleged misconduct or issues at Abbott Laboratories that have impacted the company's shareholders. The law firm is encouraging affected investors to join the class action before the upcoming deadline.</data>
    </edge>
    <edge id="e97" source="87" target="74">
      <data key="d3">7.0</data>
      <data key="d4">lawsuit against Abbott...</data>
      <data key="d6">Shareholders Foundation announced a lawsuit against Abbott Laboratories</data>
    </edge>
    <edge id="e98" source="88" target="74">
      <data key="d3">7.0</data>
      <data key="d4">Securities buy rating...</data>
      <data key="d6">Bank of America Securities has a buy rating on Abbott Laboratories</data>
    </edge>
    <edge id="e99" source="89" target="74">
      <data key="d3">5.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">BTIG lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e100" source="90" target="74">
      <data key="d3">5.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">Mizuho lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e101" source="91" target="74">
      <data key="d3">5.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">Piper Sandler lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e102" source="92" target="74">
      <data key="d3">5.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">Bernstein lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e103" source="93" target="74">
      <data key="d3">5.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">Citi lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e104" source="94" target="74">
      <data key="d3">1.0</data>
      <data key="d4">price target Abbott...</data>
      <data key="d6">Wells Fargo lowered their price target on Abbott Laboratories</data>
    </edge>
    <edge id="e105" source="95" target="74">
      <data key="d3">42.0</data>
      <data key="d4">investigating claims behalf...</data>
      <data key="d6">Pomerantz Law Firm is investigating claims on behalf of investors of Abbott Laboratories</data>
    </edge>
    <edge id="e106" source="96" target="74">
      <data key="d3">16.0</data>
      <data key="d4">Counsel encouraging Abbott...</data>
      <data key="d6">Rosen, Global Investor Counsel is encouraging Abbott Laboratories investors to secure counsel before the October 31 deadline in the securities class action</data>
    </edge>
    <edge id="e107" source="97" target="74">
      <data key="d3">14.0</data>
      <data key="d4">encouraging Abbott Laboratories...</data>
      <data key="d6">Moore Kuehn, PLLC is encouraging Abbott Laboratories investors to contact the law firm</data>
    </edge>
    <edge id="e108" source="98" target="74">
      <data key="d3">9.0</data>
      <data key="d4">Trial Attorneys encouraging...</data>
      <data key="d6">Hagens Berman, National Trial Attorneys is encouraging Abbott Laboratories investors with significant losses to contact the firm's attorneys</data>
    </edge>
    <edge id="e109" source="74" target="99">
      <data key="d3">1.0</data>
      <data key="d4">investors file lead...</data>
      <data key="d6">The deadline for investors to file a lead plaintiff motion in the securities class action lawsuit against Abbott Laboratories</data>
    </edge>
    <edge id="e110" source="100" target="74">
      <data key="d3">34.0</data>
      <data key="d4">law firm, filed...</data>
      <data key="d6">Hagens Berman, a law firm, has filed a securities class action lawsuit against Abbott Laboratories, a major pharmaceutical and healthcare company, related to its infant formula products. The lawsuit alleges that Abbott Laboratories made false and misleading statements about the safety and quality of its infant formula products, which led to significant losses for investors.

According to the descriptions provided, Hagens Berman is encouraging Abbott Laboratories investors who have experienced significant losses to contact the firm's attorneys. The law firm is representing these investors in the class action lawsuit against Abbott Laboratories.

The lawsuit appears to be focused on the issues surrounding Abbott Laboratories' infant formula products, which have been the subject of widespread media attention and regulatory scrutiny in recent months. The descriptions indicate that Hagens Berman believes Abbott Laboratories has made false or misleading statements about the safety and quality of these products, which has resulted in financial losses for investors.

It is important to note that the descriptions provided do not contain any contradictory information. The lawsuit and the firm's representation of investors appear to be consistent across the different descriptions.

In summary, Hagens Berman has filed a securities class action lawsuit against Abbott Laboratories on behalf of investors who have experienced significant losses due to the company's alleged false and misleading statements about its infant formula products. The law firm is encouraging affected investors to contact them to participate in the lawsuit.</data>
    </edge>
    <edge id="e111" source="101" target="74">
      <data key="d3">18.0</data>
      <data key="d4">law firm, encouraging...</data>
      <data key="d6">Rosen, a leading law firm, is encouraging investors of Abbott Laboratories, a major healthcare company, to secure legal counsel before an important deadline in a securities class action lawsuit.

The securities class action lawsuit against Abbott Laboratories is related to alleged misconduct or issues with the company's operations or financial reporting. Rosen, a reputable law firm specializing in securities litigation, is advising Abbott Laboratories investors to seek legal representation to protect their interests and potentially participate in the class action.

The deadline mentioned in the descriptions is likely a critical juncture in the legal proceedings, such as the deadline to join the class action or to submit claims. Rosen is urging investors to act promptly to ensure they can be part of the lawsuit and potentially recover any losses or damages they may have incurred due to the alleged wrongdoings or issues at Abbott Laboratories.

It is important for Abbott Laboratories investors to carefully review the details of the securities class action and consult with legal professionals to understand their rights and options. Rosen, as a leading law firm in this field, is well-positioned to provide guidance and representation to investors who may have been affected by the situation at Abbott Laboratories.

By encouraging investors to secure counsel before the important deadline, Rosen is ensuring that Abbott Laboratories investors have the opportunity to participate in the legal proceedings and potentially recover any losses they may have suffered. This proactive approach by Rosen demonstrates their commitment to protecting the rights of investors and holding companies accountable for any alleged misconduct or financial irregularities.

Overall, the summary highlights the ongoing securities class action against Abbott Laboratories and Rosen's efforts to assist affected investors in navigating the legal process and protecting their interests.</data>
    </edge>
    <edge id="e112" source="102" target="74">
      <data key="d3">8.0</data>
      <data key="d4">encouraging Abbott Laboratories...</data>
      <data key="d6">Investor Counsel is encouraging Abbott Laboratories investors to secure counsel before an important deadline in the securities class action lawsuit</data>
    </edge>
    <edge id="e113" source="103" target="74">
      <data key="d3">16.0</data>
      <data key="d4">Vincent Wong notifying...</data>
      <data key="d6">The Law Offices of Vincent Wong is notifying investors of a class action lawsuit involving Abbott Laboratories</data>
    </edge>
    <edge id="e114" source="104" target="74">
      <data key="d3">16.0</data>
      <data key="d4">Firm announcing lead...</data>
      <data key="d6">The Klein Law Firm is announcing a lead plaintiff deadline of October 31, 2022 in the class action filed on behalf of Abbott Laboratories shareholders</data>
    </edge>
    <edge id="e115" source="105" target="74">
      <data key="d3">14.0</data>
      <data key="d4">encouraging Abbott Laboratories...</data>
      <data key="d6">Kehoe Law Firm, P.C. is encouraging Abbott Laboratories shareholders to contact them to discuss potential legal claims</data>
    </edge>
    <edge id="e116" source="106" target="74">
      <data key="d3">16.0</data>
      <data key="d4">pursuing claims behalf...</data>
      <data key="d6">Jakubowitz Law is pursuing claims on behalf of Abbott Laboratories shareholders</data>
    </edge>
    <edge id="e117" source="107" target="74">
      <data key="d3">16.0</data>
      <data key="d4">Firm notifying shareholders...</data>
      <data key="d6">The Gross Law Firm is notifying shareholders of Abbott Laboratories of a class action lawsuit and a lead plaintiff deadline of October 31, 2022</data>
    </edge>
    <edge id="e118" source="108" target="74">
      <data key="d3">18.0</data>
      <data key="d4">Firm Abbott Laboratories...</data>
      <data key="d6">The Schall Law Firm and Abbott Laboratories

The Schall Law Firm, a legal practice based in California, is currently representing investors in a class action lawsuit against Abbott Laboratories, a major pharmaceutical and healthcare company. The lawsuit is related to losses incurred by investors in Abbott Laboratories, with the Schall Law Firm encouraging investors who have lost $100,000 or more to reach out to the firm.

The class action lawsuit against Abbott Laboratories appears to be centered around issues or events that have led to significant financial losses for the company's investors. While the specific details of the lawsuit are not provided in the given information, the Schall Law Firm's involvement suggests that there may have been some alleged wrongdoing or misrepresentation by Abbott Laboratories that has adversely impacted its stock performance and investor returns.

Abbott Laboratories is a well-known global healthcare company that operates in various segments, including pharmaceuticals, medical devices, and nutritional products. The company has a diverse portfolio of products and is known for its innovative approach to healthcare solutions. However, the current class action lawsuit indicates that there may have been some challenges or controversies within the company that have resulted in substantial financial losses for its investors.

The Schall Law Firm, as the legal representative for the investors in this case, is likely working to investigate the allegations, gather evidence, and pursue legal action against Abbott Laboratories on behalf of the affected investors. The firm's involvement suggests that they believe there is a strong case for the investors to recover their losses and hold the company accountable for any potential wrongdoing or misrepresentation.

It is important to note that the information provided does not include the specific details of the lawsuit or the allegations against Abbott Laboratories. As such, it is difficult to determine the exact nature of the issues or the potential outcomes of the legal proceedings. However, the Schall Law Firm's actions indicate that they believe the investors have a valid case and are committed to pursuing the matter on their behalf.</data>
    </edge>
    <edge id="e119" source="109" target="74">
      <data key="d3">16.0</data>
      <data key="d4">representing investors...</data>
      <data key="d6">Rosen Law Firm is representing investors in a class action lawsuit against Abbott Laboratories</data>
    </edge>
    <edge id="e120" source="110" target="74">
      <data key="d3">14.0</data>
      <data key="d4">investigating class action...</data>
      <data key="d6">Rigrodsky Law, P.A. is investigating the class action lawsuit against Abbott Laboratories</data>
    </edge>
    <edge id="e121" source="5" target="111">
      <data key="d3">18.0</data>
      <data key="d4">LLP representing investors...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP is representing investors in a class action lawsuit against Altimmune, Inc. for alleged securities fraud</data>
    </edge>
    <edge id="e122" source="111" target="112">
      <data key="d3">8.0</data>
      <data key="d4">IMPACT Phase MASH...</data>
      <data key="d6">Altimmune conducted the IMPACT Phase 2b MASH trial to evaluate its drug Pemvidutide</data>
    </edge>
    <edge id="e123" source="112" target="113">
      <data key="d3">1.0</data>
      <data key="d4">drug evaluated IMPACT...</data>
      <data key="d6">Pemvidutide was the drug evaluated in the IMPACT Phase 2b MASH trial conducted by Altimmune</data>
    </edge>
    <edge id="e124" source="114" target="117">
      <data key="d3">18.0</data>
      <data key="d4">co-founder IonQ, Inc....</data>
      <data key="d6">Christopher Monroe is a co-founder of IonQ, Inc.</data>
    </edge>
    <edge id="e125" source="115" target="117">
      <data key="d3">18.0</data>
      <data key="d4">co-founder IonQ,...</data>
      <data key="d6">Jung Sang Kim is a co-founder of IonQ, Inc.</data>
    </edge>
    <edge id="e126" source="116" target="117">
      <data key="d3">10.0</data>
      <data key="d4">headquartered College Park,...</data>
      <data key="d6">IonQ, Inc. is headquartered in College Park, MD.</data>
    </edge>
    <edge id="e127" source="117" target="118">
      <data key="d3">1.0</data>
      <data key="d4">SkyWater Technology build...</data>
      <data key="d6">IonQ is acquiring SkyWater Technology to build a vertically integrated quantum platform.</data>
    </edge>
    <edge id="e128" source="117" target="119">
      <data key="d3">9.0</data>
      <data key="d4">acquiring SkyWater Technology</data>
      <data key="d6">IonQ is acquiring SkyWater Technology</data>
    </edge>
    <edge id="e129" source="117" target="120">
      <data key="d3">8.0</data>
      <data key="d4">named CIO IonQ...</data>
      <data key="d6">Katie Arrington was named CIO of IonQ</data>
    </edge>
    <edge id="e130" source="117" target="121">
      <data key="d3">8.0</data>
      <data key="d4">named CISO IonQ...</data>
      <data key="d6">Leslie Kershaw was named CISO of IonQ</data>
    </edge>
    <edge id="e131" source="117" target="122">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">QBTS and IONQ are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e132" source="117" target="123">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">RGTI and IONQ are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e133" source="117" target="124">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">QUBT and IONQ are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e134" source="117" target="90">
      <data key="d3">7.0</data>
      <data key="d4">quantum computing, including...</data>
      <data key="d6">Mizuho highlighted advances in quantum computing, including IONQ</data>
    </edge>
    <edge id="e135" source="117" target="127">
      <data key="d3">8.0</data>
      <data key="d4">Firm representing IonQ...</data>
      <data key="d6">The Schall Law Firm is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e136" source="117" target="1">
      <data key="d3">8.0</data>
      <data key="d4">representing IonQ investors...</data>
      <data key="d6">Levi &amp; Korsinsky is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e137" source="117" target="125">
      <data key="d3">8.0</data>
      <data key="d4">Firm representing IonQ...</data>
      <data key="d6">The Klein Law Firm is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e138" source="117" target="100">
      <data key="d3">8.0</data>
      <data key="d4">representing IonQ investors...</data>
      <data key="d6">Hagens Berman is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e139" source="117" target="95">
      <data key="d3">8.0</data>
      <data key="d4">Firm representing IonQ...</data>
      <data key="d6">The Pomerantz Law Firm is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e140" source="117" target="126">
      <data key="d3">1.0</data>
      <data key="d4">representing IonQ investors...</data>
      <data key="d6">Vincent Wong is representing IonQ investors in a class action lawsuit</data>
    </edge>
    <edge id="e141" source="122" target="123">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">QBTS and RGTI are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e142" source="122" target="124">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">QUBT and QBTS are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e143" source="122" target="90">
      <data key="d3">7.0</data>
      <data key="d4">quantum computing, including...</data>
      <data key="d6">Mizuho highlighted advances in quantum computing, including QBTS</data>
    </edge>
    <edge id="e144" source="123" target="124">
      <data key="d3">2.0</data>
      <data key="d4">both quantum computing...</data>
      <data key="d6">QUBT and RGTI are both quantum computing companies mentioned in the text</data>
    </edge>
    <edge id="e145" source="123" target="90">
      <data key="d3">7.0</data>
      <data key="d4">quantum computing, including...</data>
      <data key="d6">Mizuho highlighted advances in quantum computing, including RGTI</data>
    </edge>
    <edge id="e146" source="124" target="90">
      <data key="d3">7.0</data>
      <data key="d4">quantum computing, including...</data>
      <data key="d6">Mizuho highlighted advances in quantum computing, including QUBT</data>
    </edge>
    <edge id="e147" source="100" target="117">
      <data key="d3">30.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Hagens Berman, a law firm, is representing IonQ investors in a securities class action lawsuit against the company. The lawsuit alleges that IonQ, a quantum computing company, made false and misleading statements about its business, operations, and prospects. 

Specifically, Hagens Berman is encouraging IonQ investors who have suffered significant losses to contact the firm to discuss their potential participation in the class action lawsuit. The lawsuit claims that IonQ misled investors about the company's progress in developing and commercializing its quantum computing technology.

The class action lawsuit against IonQ seeks to recover damages for investors who purchased the company's securities during the relevant time period. Hagens Berman, as the lead counsel in the case, is representing the interests of these IonQ investors and is working to hold the company accountable for any alleged wrongdoing.

The details of the lawsuit, including the specific claims and the time period covered, are not fully clear from the provided information. However, the overall message is that Hagens Berman is actively pursuing legal action on behalf of IonQ investors who have experienced significant financial losses due to the company's alleged misconduct.

In summary, Hagens Berman, a law firm, is representing IonQ investors in a securities class action lawsuit against the quantum computing company. The lawsuit alleges that IonQ made false and misleading statements about its business, operations, and prospects, leading to significant losses for investors. Hagens Berman is encouraging affected IonQ investors to contact the firm to discuss their potential participation in the lawsuit.</data>
    </edge>
    <edge id="e148" source="1" target="117">
      <data key="d3">40.0</data>
      <data key="d4">legal firm, representing...</data>
      <data key="d6">Levi &amp; Korsinsky, a legal firm, is representing IonQ, Inc. investors and shareholders in a class action lawsuit against the company. The lawsuit is related to IonQ, a quantum computing company.

According to the provided descriptions, Levi &amp; Korsinsky is notifying IonQ investors of an upcoming deadline for the class action lawsuit. The firm is representing IonQ investors and shareholders in this legal action against the company.

The class action lawsuit appears to be related to IonQ's business and operations, though the specific details of the allegations are not provided in the given information. Levi &amp; Korsinsky is taking on this case on behalf of IonQ's investors and shareholders, indicating that there may be concerns or issues with the company's conduct or performance that have led to this legal action.

It is important to note that the descriptions do not provide any information about the nature of the allegations or the specific claims being made in the lawsuit. The summary is based solely on the information that Levi &amp; Korsinsky is representing IonQ investors and shareholders in a class action lawsuit against the company.

In conclusion, Levi &amp; Korsinsky, a legal firm, is representing IonQ, Inc. investors and shareholders in a class action lawsuit against the quantum computing company. The firm is notifying IonQ investors of an upcoming deadline related to this legal action, though the specific details of the allegations are not provided in the given information.</data>
    </edge>
    <edge id="e149" source="108" target="117">
      <data key="d3">37.0</data>
      <data key="d4">Firm IonQ Schall...</data>
      <data key="d6">The Schall Law Firm and IonQ

The Schall Law Firm, a reputable legal practice, is encouraging investors in IonQ, Inc. to contact them regarding a class action lawsuit. IonQ is a leading quantum computing company that has recently been the subject of legal action.

According to the descriptions provided, the Schall Law Firm is reaching out to IonQ investors who have experienced losses of $100,000 or more. The firm is inviting these investors to connect with them regarding the ongoing class action lawsuit against the company.

The class action lawsuit appears to be related to financial losses experienced by IonQ investors. While the exact details of the lawsuit are not specified, the Schall Law Firm is positioning itself as a resource for affected investors seeking legal recourse.

It is important to note that the descriptions provided do not contain any contradictory information. The Schall Law Firm's message is consistent across the various descriptions, indicating that they are actively seeking to engage with IonQ investors who have suffered significant financial losses.

In summary, the Schall Law Firm is encouraging investors in the quantum computing company IonQ, Inc. who have experienced losses of $100,000 or more to contact the firm regarding a class action lawsuit. The firm is positioning itself as a resource for these affected investors, providing them with an opportunity to seek legal representation and potential compensation for their losses.</data>
    </edge>
    <edge id="e150" source="104" target="117">
      <data key="d3">39.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

The Klein Law Firm, a legal firm, has announced a lead plaintiff deadline of August 1, 2022 in a class action lawsuit filed on behalf of shareholders of IonQ, Inc., a quantum computing company. The class action lawsuit is being brought against IonQ by The Klein Law Firm, representing IonQ shareholders.

The lawsuit alleges certain claims against IonQ and its leadership. The specific details of the claims have not been provided in the information given. However, the fact that The Klein Law Firm has filed a class action lawsuit on behalf of IonQ shareholders suggests there may be allegations of wrongdoing or harm caused to IonQ investors.

The lead plaintiff deadline of August 1, 2022 indicates that The Klein Law Firm is seeking to establish a lead plaintiff to represent the class of IonQ shareholders in the lawsuit. This is a common procedure in class action lawsuits, where a representative plaintiff is appointed to act on behalf of the broader group of affected shareholders or investors.

In summary, The Klein Law Firm is currently representing IonQ shareholders in a class action lawsuit against the quantum computing company. The lawsuit appears to be related to claims of harm or wrongdoing affecting IonQ investors, though the specific details of the allegations have not been provided. The firm has announced a lead plaintiff deadline of August 1, 2022 as part of the legal proceedings.</data>
    </edge>
    <edge id="e151" source="101" target="117">
      <data key="d3">8.0</data>
      <data key="d4">law firm encouraging...</data>
      <data key="d6">Rosen is a law firm encouraging IonQ investors to secure counsel before the August 1 deadline in the securities class action</data>
    </edge>
    <edge id="e152" source="128" target="117">
      <data key="d3">7.0</data>
      <data key="d4">Grossman reminding IonQ...</data>
      <data key="d6">Bronstein, Gewirtz &amp; Grossman is reminding IonQ investors of the upcoming class action deadline</data>
    </edge>
    <edge id="e153" source="103" target="117">
      <data key="d3">16.0</data>
      <data key="d4">Vincent Wong notifying...</data>
      <data key="d6">The Law Offices of Vincent Wong are notifying investors of a class action lawsuit against IonQ, Inc. IonQ is a leading quantum computing company that has been accused of making false and misleading statements to investors.

According to the class action lawsuit, IonQ allegedly made statements about the company's technology and commercialization efforts that were not accurate. The lawsuit claims that IonQ overstated the company's business and financial prospects, leading to an inflated stock price.

The Law Offices of Vincent Wong are representing investors who purchased IonQ securities between March 30, 2021, and October 5, 2021. The lawsuit alleges that IonQ's statements during this period were false and misleading, and that the company failed to disclose material information about the state of its business.

IonQ is a prominent player in the quantum computing industry, and the class action lawsuit could have significant implications for the company and its investors. Quantum computing is a rapidly evolving field with the potential to revolutionize various industries, and IonQ has been at the forefront of this technology.

The Law Offices of Vincent Wong are encouraging all investors who purchased IonQ securities during the relevant time period to contact the firm to discuss their legal options. The firm is committed to protecting the rights of investors and holding companies accountable for any false or misleading statements.

In summary, the class action lawsuit against IonQ alleges that the company made false and misleading statements about its technology and business prospects, leading to an inflated stock price. The Law Offices of Vincent Wong are representing investors who were affected by these alleged actions and are seeking to recover their losses.</data>
    </edge>
    <edge id="e154" source="107" target="117">
      <data key="d3">9.0</data>
      <data key="d4">Firm IonQ, Inc....</data>
      <data key="d6">The Gross Law Firm and IonQ, Inc.

The Gross Law Firm, a legal practice, has notified shareholders of IonQ, Inc., a quantum computing company, about a class action lawsuit and a lead plaintiff deadline. The law firm is informing shareholders of the ongoing legal proceedings against IonQ.

According to the information provided, The Gross Law Firm has initiated a class action lawsuit against IonQ. The lawsuit is likely related to the company's operations, financial performance, or other matters that may have impacted shareholders. The law firm is encouraging IonQ shareholders to participate in the class action lawsuit by establishing a lead plaintiff deadline.

IonQ is a prominent player in the quantum computing industry, developing advanced quantum computing technologies and solutions. The company's involvement in the class action lawsuit suggests that there may have been issues or concerns raised by shareholders regarding the company's practices, disclosures, or other aspects of its business.

The Gross Law Firm's notification to IonQ shareholders indicates that the law firm is representing the interests of these shareholders and seeking to address any potential wrongdoings or misrepresentations by the company. The class action lawsuit is a legal mechanism that allows a group of shareholders to collectively pursue claims against a company, with the potential for financial compensation or other remedies.

It is important to note that the details of the class action lawsuit, including the specific allegations and the potential outcomes, are not provided in the given information. The summary presented here is based on the limited data available, which includes the notification of the lawsuit and the lead plaintiff deadline.

In conclusion, The Gross Law Firm has initiated a class action lawsuit against IonQ, Inc., a prominent quantum computing company, on behalf of its shareholders. The law firm is encouraging IonQ shareholders to participate in the legal proceedings by establishing a lead plaintiff deadline. The outcome of this lawsuit and its potential impact on IonQ and its shareholders remain to be seen as the legal process unfolds.</data>
    </edge>
    <edge id="e155" source="117" target="129">
      <data key="d3">1.0</data>
      <data key="d4">lawsuit against IonQ...</data>
      <data key="d6">The class action lawsuit against IonQ has a lead plaintiff deadline of August 1, 2022</data>
    </edge>
    <edge id="e156" source="130" target="107">
      <data key="d3">8.0</data>
      <data key="d4">Firm notified shareholders...</data>
      <data key="d6">The Gross Law Firm has notified shareholders of IonQ, Inc. of a class action lawsuit and a lead plaintiff deadline</data>
    </edge>
    <edge id="e157" source="130" target="103">
      <data key="d3">8.0</data>
      <data key="d4">Vincent Wong notified...</data>
      <data key="d6">The Law Offices of Vincent Wong has notified investors of a class action lawsuit involving IonQ, Inc.</data>
    </edge>
    <edge id="e158" source="130" target="98">
      <data key="d3">9.0</data>
      <data key="d4">Trial Attorneys encouraging...</data>
      <data key="d6">Hagens Berman, National Trial Attorneys is encouraging IonQ, Inc. (IONQ) investors with significant losses to contact the firm's attorneys before the August 1st deadline in a securities fraud action</data>
    </edge>
    <edge id="e159" source="130" target="108">
      <data key="d3">8.0</data>
      <data key="d4">Firm encouraging investors...</data>
      <data key="d6">The Schall Law Firm is encouraging investors in IonQ, Inc. with losses of $100,000 to contact the firm</data>
    </edge>
    <edge id="e160" source="130" target="104">
      <data key="d3">9.0</data>
      <data key="d4">Firm announced lead...</data>
      <data key="d6">The Klein Law Firm has announced a lead plaintiff deadline of August 1, 2022 in the class action filed on behalf of IonQ, Inc. limited shareholders</data>
    </edge>
    <edge id="e161" source="130" target="1">
      <data key="d3">8.0</data>
      <data key="d4">notifying IonQ, Inc....</data>
      <data key="d6">Levi &amp; Korsinsky is notifying IonQ, Inc. investors of a class action lawsuit and an upcoming deadline</data>
    </edge>
    <edge id="e162" source="130" target="95">
      <data key="d3">1.0</data>
      <data key="d4">Firm reminding shareholders...</data>
      <data key="d6">The Pomerantz Law Firm is reminding shareholders with losses on their investment in IonQ, Inc. of a class action lawsuit and upcoming deadline</data>
    </edge>
    <edge id="e163" source="98" target="117">
      <data key="d3">9.0</data>
      <data key="d4">Trial Attorneys encouraging...</data>
      <data key="d6">Hagens Berman, National Trial Attorneys is encouraging IonQ, Inc. (IONQ) investors with significant losses to contact the firm's attorneys before the August 1st deadline in a securities fraud action</data>
    </edge>
    <edge id="e164" source="95" target="117">
      <data key="d3">23.0</data>
      <data key="d4">Firm representing shareholders...</data>
      <data key="d6">The Pomerantz Law Firm is representing shareholders of IonQ, Inc. in a class action lawsuit. The law firm is reminding IonQ shareholders of the ongoing lawsuit and an upcoming deadline related to their investment losses.

According to the provided descriptions, the Pomerantz Law Firm is acting on behalf of IonQ shareholders who have experienced losses on their investment in the company. The law firm is pursuing a class action lawsuit on behalf of these shareholders and has issued reminders about the lawsuit and an upcoming deadline.

The class action lawsuit appears to be related to IonQ, a quantum computing company. The Pomerantz Law Firm is representing the interests of IonQ shareholders who have suffered investment losses, likely due to issues or events surrounding the company.

While the specific details of the lawsuit and the nature of the investment losses are not provided, the Pomerantz Law Firm is taking legal action to protect the rights and interests of IonQ shareholders. The firm is encouraging affected shareholders to participate in the class action lawsuit and be aware of the upcoming deadline.

In summary, the Pomerantz Law Firm is representing IonQ shareholders in a class action lawsuit related to investment losses. The firm is actively engaging with IonQ shareholders to ensure their interests are protected and to provide them with information about the ongoing legal proceedings.</data>
    </edge>
    <edge id="e165" source="126" target="117">
      <data key="d3">8.0</data>
      <data key="d4">Vincent Wong notifying...</data>
      <data key="d6">The Law Offices of Vincent Wong are notifying investors of the class action lawsuit involving IonQ</data>
    </edge>
    <edge id="e166" source="117" target="101">
      <data key="d3">1.0</data>
      <data key="d4">IonQ investors with...</data>
      <data key="d6">Rosen is encouraging IonQ investors with losses over $100K to secure counsel before an important deadline</data>
    </edge>
    <edge id="e167" source="109" target="117">
      <data key="d3">8.0</data>
      <data key="d4">Firm encouraging IonQ...</data>
      <data key="d6">The Rosen Law Firm is encouraging IonQ investors to secure counsel for the securities class action</data>
    </edge>
    <edge id="e168" source="131" target="130">
      <data key="d3">1.0</data>
      <data key="d4">deadline IonQ class...</data>
      <data key="d6">The lead plaintiff deadline for the IonQ class action lawsuit is August 1, 2022</data>
    </edge>
    <edge id="e169" source="117" target="132">
      <data key="d3">14.0</data>
      <data key="d4">other companies Electronic...</data>
      <data key="d6">IonQ competes with other companies in the Electronic Technology and Computer Processing Hardware sectors</data>
    </edge>
    <edge id="e170" source="117" target="133">
      <data key="d3">8.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Total revenue is a key financial metric for IonQ</data>
    </edge>
    <edge id="e171" source="117" target="134">
      <data key="d3">8.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Net income is a key financial metric for IonQ</data>
    </edge>
    <edge id="e172" source="117" target="135">
      <data key="d3">8.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Earnings per share is a key financial metric for IonQ</data>
    </edge>
    <edge id="e173" source="117" target="136">
      <data key="d3">8.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Net profit margin is a key financial metric for IonQ</data>
    </edge>
    <edge id="e174" source="117" target="137">
      <data key="d3">8.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Free cash flow is a key financial metric for IonQ</data>
    </edge>
    <edge id="e175" source="117" target="138">
      <data key="d3">1.0</data>
      <data key="d4">key financial metric...</data>
      <data key="d6">Debt-to-equity ratio is a key financial metric for IonQ</data>
    </edge>
    <edge id="e176" source="1" target="139">
      <data key="d3">1.0</data>
      <data key="d4">used Globe Newswire...</data>
      <data key="d6">Levi &amp; Korsinsky used Globe Newswire to announce the filing of the securities class action lawsuit</data>
    </edge>
    <edge id="e177" source="1" target="6">
      <data key="d3">9.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Joseph E. Levi is an attorney at Levi &amp; Korsinsky representing Vistagen Therapeutics shareholders</data>
    </edge>
    <edge id="e178" source="1" target="7">
      <data key="d3">9.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Ed Korsinsky is an attorney at Levi &amp; Korsinsky representing Vistagen Therapeutics shareholders</data>
    </edge>
    <edge id="e179" source="140" target="1">
      <data key="d3">9.0</data>
      <data key="d4">involved Levi...</data>
      <data key="d6">Levi &amp; Korsinsky is involved in the Levi Korsinsky trial as a law firm representing investors in securities class action lawsuits</data>
    </edge>
    <edge id="e180" source="1" target="141">
      <data key="d3">8.0</data>
      <data key="d4">filed securities fraud...</data>
      <data key="d6">Levi &amp; Korsinsky filed a securities fraud class action lawsuit against Capricor Therapeutics</data>
    </edge>
    <edge id="e181" source="1" target="66">
      <data key="d3">8.0</data>
      <data key="d4">served lead counsel...</data>
      <data key="d6">Levi &amp; Korsinsky served as lead counsel in a securities class action lawsuit against Tronox Holdings PLC</data>
    </edge>
    <edge id="e182" source="1" target="69">
      <data key="d3">8.0</data>
      <data key="d4">notified investors possible...</data>
      <data key="d6">Levi &amp; Korsinsky notified investors of a possible fraud case against Alector, Inc.</data>
    </edge>
    <edge id="e183" source="1" target="142">
      <data key="d3">8.0</data>
      <data key="d4">reminded investors pending...</data>
      <data key="d6">Levi &amp; Korsinsky reminded investors of a pending class action lawsuit against Altimmune</data>
    </edge>
    <edge id="e184" source="1" target="9">
      <data key="d3">8.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky filed a class action lawsuit against Vistagen Therapeutics, Inc.</data>
    </edge>
    <edge id="e185" source="1" target="130">
      <data key="d3">1.0</data>
      <data key="d4">mentioned relation Levi...</data>
      <data key="d6">IonQ, Inc. was mentioned in relation to Levi &amp; Korsinsky's class action litigation work</data>
    </edge>
    <edge id="e186" source="143" target="1">
      <data key="d3">1.0</data>
      <data key="d4">judge disqualified Levi...</data>
      <data key="d6">The California federal judge disqualified Levi &amp; Korsinsky from serving as lead counsel due to the firm issuing "false press releases" to attract clients</data>
    </edge>
    <edge id="e187" source="1" target="144">
      <data key="d3">1.0</data>
      <data key="d4">Levi Korsinsky occurred...</data>
      <data key="d6">The disqualification of Levi &amp; Korsinsky occurred in a California federal court</data>
    </edge>
    <edge id="e188" source="66" target="5">
      <data key="d3">18.0</data>
      <data key="d4">LLP been appointed...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP has been appointed as lead counsel in the lawsuit against Tronox Holdings PLC</data>
    </edge>
    <edge id="e189" source="66" target="147">
      <data key="d3">9.0</data>
      <data key="d4">Holdings PLC have...</data>
      <data key="d6">Investors in Tronox Holdings PLC have filed a federal securities class action lawsuit against the company</data>
    </edge>
    <edge id="e190" source="145" target="146">
      <data key="d3">16.0</data>
      <data key="d4">Dooley appointed Jason...</data>
      <data key="d6">Judge Kari A. Dooley appointed Jason D. Smith as Lead Plaintiff in the lawsuit</data>
    </edge>
    <edge id="e191" source="145" target="5">
      <data key="d3">9.0</data>
      <data key="d4">Dooley approved selection...</data>
      <data key="d6">Judge Kari A. Dooley approved the selection of Levi &amp; Korsinsky, LLP as Lead Counsel</data>
    </edge>
    <edge id="e192" source="5" target="147">
      <data key="d3">1.0</data>
      <data key="d4">LLP been appointed...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP has been appointed as lead counsel in the federal securities class action lawsuit</data>
    </edge>
    <edge id="e193" source="2" target="0">
      <data key="d3">8.0</data>
      <data key="d4">Biologics License Application...</data>
      <data key="d6">Capricor submitted a Biologics License Application to the FDA for approval of deramiocel</data>
    </edge>
    <edge id="e194" source="2" target="40">
      <data key="d3">9.0</data>
      <data key="d4">approves Biologics License...</data>
      <data key="d6">The FDA reviews and approves Biologics License Applications for biological products like cell therapies</data>
    </edge>
    <edge id="e195" source="3" target="0">
      <data key="d3">9.0</data>
      <data key="d4">developing deramiocel lead...</data>
      <data key="d6">Capricor Therapeutics is developing deramiocel as its lead cell therapy candidate drug</data>
    </edge>
    <edge id="e196" source="41" target="0">
      <data key="d3">1.0</data>
      <data key="d4">Complete Response Letter...</data>
      <data key="d6">The FDA issued a Complete Response Letter to Capricor denying the BLA for deramiocel</data>
    </edge>
    <edge id="e197" source="0" target="5">
      <data key="d3">9.0</data>
      <data key="d4">filing securities fraud...</data>
      <data key="d6">Levi &amp; Korsinsky is filing a securities fraud class action lawsuit against Capricor Therapeutics on behalf of investors</data>
    </edge>
    <edge id="e198" source="6" target="5">
      <data key="d3">9.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Joseph E. Levi is an attorney at Levi &amp; Korsinsky representing investors in the Capricor Therapeutics lawsuit</data>
    </edge>
    <edge id="e199" source="7" target="5">
      <data key="d3">1.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Ed Korsinsky is an attorney at Levi &amp; Korsinsky representing investors in the Capricor Therapeutics lawsuit</data>
    </edge>
  </graph>
</graphml>